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Telomerase activity is low to absent in somatic cells, but reactivated in over ninety 
percent of malignancies, allowing for prolonged cellular proliferation which would 
otherwise be limited by critical telomere shortening. TERT, the catalytic subunit of 
telomerase, is regulated via multiple mechanisms, including activating promoter 
mutations, promoter methylation, histone modifications, and alternative splicing. 
However, it remains poorly understood how these regulatory strategies cooperate to 
activate telomerase or how structural changes such as TERT promoter mutations serve to 
further increase telomerase expression. 
Herein, we have characterized TERT promoter methylation in differentiated thyroid 
cancer (DTC) cell lines and normal thyroid tissue by targeted bisulfite sequencing for the 
first time. Consistent with reports in other cancers, we found localized hypomethylation 
of the minimal promoter immediately surrounding the transcription start site, including 
patterns suggesting allele-specific methylation. Further upstream, the promoter was 
densely methylated, but with foci of hypomethylation harboring previously unreported 
binding sites for the transcriptional activators MYC and GSC.  
To further investigate allele-specific methylation, we utilized nanopore Cas9 targeted 
sequencing in DTC cell lines heterozygous for the TERT promoter mutation, and found 
the mutant TERT promoter allele to be significantly less methylated than the wildtype 
allele. With chromatin immunoprecipitation followed by Sanger sequencing, we 
demonstrated that in heterozygous mutant cells, the transcriptional activators GABPA 
and MYC bind only to the mutant TERT allele. In addition, the activating and repressive 
chromatin marks H3K4me3 and H3K27me3, respectively, exclusively bind mutant and 
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wildtype alleles. Lastly, utilizing coding SNPs and long read sequencing, we determined 
that TERT is only expressed from the mutant allele. 
Future work will continue to further delineate the effect of the TERT promoter mutation 
on activation of TERT. Using CRISPR/Cas9 technology to edit the TERT promoter 
mutation status and characterize resulting TERT regulation will provide further 
mechanistic insight. The link between these regulatory strategies could offer additional 
insight into cellular control of active telomerase in thyroid cancer, and be applied more 
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Chapter 1: Telomerase Reverse Transcriptase (TERT) 
Regulation in Thyroid Cancer 
Adapted from: BA. McKelvey, et al. Telomerase Reverse Transcriptase (TERT) 
Regulation in Thyroid Cancer: A Review. Frontiers in Endocrinology. 2020 July.  
In contrast to stem cells, non-transformed somatic cells have a limited capacity to divide 
in tissue culture before cell division ceases. This is known as cellular senescence and the 
number of times a normal human somatic cell population will divide before cell division 
stops is referred to as the Hayflick limit (1). Cellular senescence results from the 
progressive shortening of chromosomal ends or telomeres, consisting of identical 
hexamer repeats, with each cell division. This phenomenon is due to the end replication 
problem, a shortcoming of semiconservative DNA replication, which cannot complete the 
synthesis of chromosomal ends (2). This critical shortening of telomeres continues until 
reactivation of the enzyme, telomerase, facilitates the resynthesizing of telomeres of 
sufficient length to allow continued cellular replication. Telomere lengthening can also 
occasionally occur through the alternative lengthening of telomeres (ALT) pathway, 
which extends telomeres without telomerase activity through recombination-dependent 
pathways (3).  
 
Telomerase is composed of two subunits: an RNA component, telomerase RNA (TR), 
serving as a template for telomere hexamer repeat addition onto DNA and, the catalytic 
component telomerase reverse transcriptase (TERT), responsible for reverse transcribing 
the hexamer repeats onto chromosomal ends (4). Not only is telomerase active in 
2 
 
embryonic and stem cells, it is also upregulated in over 90% of malignancies, including 
thyroid cancer, enabling the unlimited replication of cancer cells (5–8). 
 
TERT activation in cancer occurs through a variety of mechanisms. These include 
activating promoter mutations, alterations in promoter DNA methylation, chromatin 
remodeling, copy number alterations, and alternative splicing of TERT (9–13). Because 
telomerase plays a key role in carcinogenesis, understanding TERT regulation and 
telomerase activation in thyroid cancer is critical to understanding its pathogenesis. 
Indeed, two TERT regulatory mechanisms, TERT promoter mutations and TERT promoter 




Activation of TERT transcription can be achieved by heterozygous point mutations at the 
TERT promoter. The two most common activating mutations are upstream of the TERT 
translation start site at -124 and -146, respectively, and both are cytosine to thymine 
mutations, -124C>T and -146 C>T (Figure 1) (17–19). These TERT promoter mutations 
are not present in benign thyroid tumors or normal thyroid cells. Their prevalence, 
however, increases with more aggressive thyroid cancer subtypes and advanced stages of 
disease. Indeed, TERT mutations are present in only 11.3% of well differentiated 
papillary thyroid cancer (PTC) and 17.1% of follicular thyroid cancer (FTC), but present 
in 32% of widely invasive Hürthle cell carcinoma (HCC), compared to 5% of minimally 
invasive HCC, and in 43.2% of poorly differentiated thyroid cancer (PDTC) and 40.1% 
3 
 
of anaplastic thyroid cancer (ATC) (20, 21). Furthermore, the TERT promoter mutations 
are found in almost all thyroid cancer cell lines, even those derived from well-
differentiated thyroid cancer (DTC) subtypes, in either the heterozygous or homozygous 
mutant state, indicative of their important role in cellular proliferation (11).  
 
As seen in the TCGA data, the presence of TERT mutation is also strongly associated 
with high risk of tumor recurrence, older age, higher MACIS (Metastasis, patient Age, 
Completeness of resection, local Invasion, and tumor Size) scores, and less-differentiated 
PTC (22). In support of the TCGA data, in a large study of thyroid cancers in which 
anaplastic carcinoma coexisted with papillary carcinoma, a multivariate comparison 
between the antecedent papillary carcinoma components and control papillary 
carcinomas without anaplastic transformation showed that TERT mutations were 
independently associated with anaplastic transformation (23). Further studies have also 
highlighted the association of the TERT promoter mutation and non-radioiodine avidity 
of metastatic disease (24, 25). 
 
Mechanism of TERT Mutation Activation  
Likely key to their effect, both TERT promoter mutations result in a novel 11 base pair 
binding site for the E-twenty-six (ETS) transcription factor family. The -124C>T 
mutation, however, elicits a higher activation of TERT compared to the -146C>T 
mutation and, is more common (20, 26). The activating GA Binding Protein 
Transcription Factor Subunit Alpha (GABPA), a member of the ETS family, binds at the 
TERT promoter mutation site as a heterotetramer with its counterpart, GABPB, in 
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multiple cancer types, including thyroid cancer (26, 27). In PTC cell lines, GABPA 
knockdown significantly lowered TERT expression in both wildtype and TERT promoter 
mutant cells, and in a luciferase activity assay, GABPA knockdown led to significant 
down regulation of the mutant TERT promoter. However, in an analysis of papillary 
thyroid cancers and TCGA data, an inverse relationship was found between GABPA 
expression and TERT expression in TERT promoter mutant tumors, highlighting the need 
for further study of TERT mutation activation (28).  
 
Recently, another ETS factor, ETS Variant 5 (ETV5), was also found to bind the mutant 
TERT promoter and, bound at higher levels than GABPA in ATC cell lines. Conversely, 
GABPA bound at higher levels than ETV5 in well differentiated thyroid cancer-derived 
cell lines (29), implicating potentially different roles of these specific ETS factors in 
well-differentiated and poorly differentiated cancers.  
 
Synergistic Effects of TERT and BRAFV600E Mutation 
The BRAFV600E mutation is also common in thyroid cancer. The BRAFV600E mutation 
is a single nucleotide mutation at codon 600, resulting in a substitution of glutamic acid 
for valine in the BRAF protein, a serine/threonine protein kinase that plays a role in the 
mitogen-activated protein kinase (MAPK) pathway/ERK signaling pathway. The 
BRAFV600E mutation is more abundant in classic PTC (51%) than in the follicular 
variant of PTC (FVPTC, 24%) or FTC (1.4%) (30). The BRAFV600E mutation acts 
synergistically with TERT promoter mutations and the presence of both mutations is 
associated with greater cancer aggressiveness, lymph node and distant metastasis, 
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advanced tumor stage, recurrence, and increased mortality in patients with PTC (31–33). 
The mutation may also be responsible for increased activation of the ETS factor family 
through activation of the MAPK pathway. There are two prevailing proposed 
mechanisms for the activation of TERT by the BRAFV600E mutation and the MAPK 
pathway. In one study of PTC cell lines, the MAPK pathway activates the transcription 
factor c-FOS, which can in turn bind to the GABPB promoter to increase its expression. 
This then leads to increase in GABPA-GABPB complex formation, which binds to the 
mutant TERT promoter to activate TERT (27). Alternatively, another study in PTCs from 
the TCGA study cohort shows upregulation of ETS factors ETV1, ETV4, and ETV5 in 
tumors that concomitantly harbored both BRAFV600E and TERT mutations and, 
demonstrated MAPK pathway activation. In cell lines, these ETS factors were found to 
bind to the mutant TERT promoter and upregulate transcription (34).  
 
Epigenetic Alterations 
Epigenetic changes are stably inherited during cell division and occur at DNA or 
chromatin levels, but do not alter the primary base sequence (35). At the DNA level, 
epigenetic alterations occur by methylation of the cytosine nucleotide in cytosine-guanine 
dinucleotides (CpGs). In higher eukaryotes, DNA methylation at CpG sites in and around 
gene promoter regions controls and regulates gene expression. CpG methylation is 
directed by DNA methyltransferases (DNMTs) which methylate the fifth carbon of the 
pyrimidine ring of cytosine (36). The principal methyltransferase, DNMT1, adds methyl 




Many CpG sites are clustered into CpG islands that are typically one thousand base pairs 
long and have high GC content. Approximately eighty percent of CpG sites are 
methylated in mammals, largely in intergenic regions known as heterochromatin, while 
most sites in promoters and first exons remain unmethylated (38, 39). The promoter and 
transcription start site (TSS) tends to be unmethylated in actively transcribed genes, since 
methylated DNA is associated with gene silencing through both interference of 
transcription factor binding and, by affecting chromatin architecture (40). Importantly, 
aberrant DNA methylation is a hallmark of cancer cells, and tends to occur early in 
cancer development (41). In cancer, characteristic changes in methylation patterns 
involve both genome-wide CpG hypomethylation, which occurs predominantly in 
intergenic regions, and hypermethylation of CpG islands at promoters. Promoter 
hypermethylation may result in silencing of tumor suppressors, and promoter 
hypomethylation can result in activation of proto-oncogenes (42). Intergenic 
hypomethylation may also lead to expression of dormant non-coding RNA species and 
otherwise suppressed genetic elements transcribed from normally silent regions of the 
genome (43–45). 
 
The TERT promoter is within a 4 kb CpG island and has a high GC content of 
approximately 70% (46). The precise pattern of promoter methylation that results in 
activation of TERT in cancer is still under investigation. However, previous studies in a 
variety of cancer cell lines as well as solid tumors and hematological malignancies show 
a unique methylation pattern of TERT. Its promoter region surrounding the TSS [-200 to 
+100 relative to TSS] is unmethylated, while the upstream promoter region [-650 to -200] 
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is hypermethylated (13, 47). The unmethylated TSS allows for transcription to occur by 
availing its binding sites for activators such as MYC and, when the TERT promoter 
mutation is present, ETS family factors (Figure 1) (48). The role of the hypermethylated 
upstream promoter, and its association with TERT expression, however, is unknown.  
 
TERT Upstream Methylation in Thyroid Cancer 
A 2016 study of medullary thyroid cancer (MTC) and normal thyroid tissue samples 
quantified the TERT upstream promoter methylation at eight CpG sites. Sporadic MTCs 
had a significantly higher methylation level (12-90.3%) compared to normal thyroid 
tissues (approximately 10%). And, this methylation pattern positively correlated with 
expression of TERT and telomerase activation. Further, high methylation of the upstream 
TERT promoter correlated with shortened survival in patients with MTC (16). A 2018 
study of follicular neoplasms found the upstream TERT promoter was methylated 
significantly higher in FTC (13%) than follicular adenoma (8%) (49). Lastly, a study of 
upstream TERT promoter methylation patterns in 312 PTC, FTC, MTC, and ATC 
patients found significantly higher upstream DNA methylation in patients with cancer 
recurrence than in patients whose tumors did not recur. In patients with a recurrence, 
upstream TERT promoter methylation was also associated with higher tumor stage and 
the presence of lymph node metastasis (15).  
 
TERT Histone Mark Modifications  
In addition to methylation aberrations, epigenetic changes in the histone code can also 
modify gene expression by altering the chromatin state from a closed, inactive state to an 
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open, actively transcribed state. The histone mark H3K27me3 maintains heterochromatin 
and recruitment of the polycomb repressor complex (PRC) for silenced genes (50). 
Alternatively, the H3K4me3 mark maintains actively transcribed genes in the open 
confirmation to enable access for transcriptional activators to bind (51). Telomerase 
negative primary cells exhibit high levels of the silencing H3K27me3 mark at the TERT 
promoter, compared to telomerase positive cancer cell lines (52), which exhibit the 
activating H3K4me3 mark (53). Further study is needed to determine the chromatin 
marks associated with the TERT promoter in thyroid cancer. 
 
Allele-Specific Regulation 
Recently, in order to further delineate TERT transcriptional regulation, studies have been 
conducted in many cancer subtypes to examine allele-specific regulation and the TERT 
mutation. Allele-specific regulation, resulting in expression of only one allele, is 
classically described by the well-known phenomenon, inactivation of one of the X 
chromosomes in all females. This is due to epigenetic effects, in which one of the two X 
chromosomes is stably transcriptionally silenced by methylation early in development. 
(54).  
 
A study in 2015 of multiple cancer cell lines showed monoallelic expression of TERT in 
cell lines heterozygous for the TERT promoter mutation, although the study did not 
elucidate which allele was transcribed (55). Further studies expanded upon this by 
showing allele-specific regulation of the alleles, in which the TERT promoter mutant 
allele exhibits the H3K24me2/3 activating histone modification as well as binding of 
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RNA polymerase II, the polymerase responsible for actively transcribing genes. The 
activating ETS factor GABPA has also been shown in multiple cell lines to bind in an 
allele-specific manner to the mutant TERT promoter only. This would be expected since 
the mutation specifically creates the ETS factor binding site. The wild type TERT allele, 
however, displays the silencing histone mark H3K27me3 and, is associated with the PRC 
(52, 56).  
 
TERT Allele-Specific Regulation in Thyroid Cancer 
Allele-specific regulation in thyroid cancer cell lines has recently been a topic of interest. 
Bullock et al.’s recent study of two heterozygous mutant thyroid cancer cell lines 
suggested allele-specific regulation of TERT, showing monoallelic expression of TERT in 
the ATC and PTC cell lines. In the cell lines H3K4me3 was associated with the mutant 
allele only, while a majority of H3K27me3 was associated with the wildtype allele. In 
one ATC line, the ETS factor ETV5 bound in an allele-specific manner (29). Further 
characterization of allele-specific regulation in thyroid cancer is necessary. 
 
Alternative Splicing  
Modulation of alternative splicing is detected in multiple types of cancers, where cancer 
cells utilize an alternative splicing switch that results in discernible isoform signatures 
(57). This switching is nonrandom and also seen in tissue development, including the 
TERT splice switch, well characterized in kidney development and various cancer cell 
types (58–70). This mode of TERT regulation has been proposed to be necessary due to 
the difficulty to completely cease transcription, since even very small amounts of 
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transcript may have significant cellular effects, given the limited number of cellular 
targets, i.e., 92 telomeres in the normal human cell (9). Previous studies have shown 
TERT expression is undetectable in normal thyroid tissue, low to absent in benign tumors, 
and elevated in thyroid cancers (20). Cancer cells with active telomerase have an average 
of 20 TERT transcripts per cell resulting in 100-500 active telomerase complexes (71). 
Alternative splicing yielding inactive and/or inhibitory forms of TERT allows for 
downregulation of telomerase activity without complete repression of transcription 
(Figure 1).  
 
Over twenty different isoforms of TERT have so far been reported, with the most 
common being various deletions in the reverse transcriptase domain (72). The most 
common TERT isoforms include the following: 1)  full-length transcript, the only isoform 
resulting in active telomerase (73, 74); 2)  the α deletion isoform, an in-frame deletion of 
36 base pairs in exon six resulting in a dominant negative inhibitor of telomerase (75); 3) 
the β deletion isoform, a 182 base pair deletion of exons seven and eight resulting in a 
reading frame shift forming a truncated TERT transcript that is sent for nonsense 
mediated decay (76) and; 4) the α/β dual deletion isoform. Studies of TERT alternative 
splicing in multiple cancer types have shown the highest expressed isoform in cancer is 
the full-length isoform, which correlates with higher telomerase activity (59, 60, 68).  
 
TERT Splicing in MTC 
A study of 42 MTC tumors found TERT expression and telomerase activity in 50% 
(21/42) of the tumors. And, over two-thirds of the telomerase positive cancers (15/21) 
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showed expression of the full-length TERT transcript, higher telomerase activity and were 
associated with a significantly shorter patient survival time (77).  
 
TERT Splicing in DTC 
Our group showed, in a study of 60 malignant tumors (PTC, FVPTC, FTC, and HCC) 
and 73 benign lesions, that malignant tumors showed a higher amount of the full-length 
isoform than the inactive TERT isoforms, while conversely, the benign tumors showed 
higher levels of the deletion isoforms (78). Further, only the full-length transcript 
correlated with telomerase activity (70, 78). By computing the proportion of full-length 
isoform to the deletion isoforms, we found the percentage score sorted thyroid tumors 
into subtypes; with the high full-length fractions of TERT found in PTC, HCC, and FTC, 
while intermediate fractions were found in FVPTC, Hürthle cell adenomas, and follicular 
adenomas and finally, low fractions in adenomatoid nodules (70).  
 
Clinical Significance  
In summary, TERT is regulated by a variety of mechanisms, indicative of the complex 
regulatory effort cells exert to control telomerase activity. The majority of malignancies 
reactivate TERT expression, which in turn activates telomerase, to allow for continued 
proliferation. TERT reactivation is important for cancer cells, as cancer cells have 
significantly shorter telomeres. Shortened telomeres are found in PTC, FTC, HCC and 
MTC compared to normal thyroid tissue and benign thyroid nodules (70, 77, 79-81). In 
PTC tumors, short telomeres were significantly correlated with TERT promoter mutations 
and older age (82). While all of these regulatory strategies are altered in thyroid cancer, 
12 
 
and may play a significant role in TERT activation, these altered regulatory mechanisms 
have not yet been leveraged clinically.  
 
TERT mRNA expression has been proposed as a prognostic marker, independent of the 
TERT promoter mutation. A study in PTC found a subset of wildtype TERT tumors with 
high TERT expression, which correlated with a higher recurrence rate (83). However, 
other studies have shown that TERT immunohistochemistry (IHC), or measurement of 
protein expression is not a useful clinical tool for prognostication. A study in FTC 
showed no correlation between TERT mRNA expression and TERT immunoreactivity 
(84), and a study in PTC showed no correlation with TERT IHC and clinicopathological 
traits (85).  
 
Presence of the TERT promoter mutation, however, may be promising for future use to 
guide clinical decision making and treatment. The presence of the TERT promoter 
mutation is indicative of worse clinicopathological factors in thyroid cancer. The thyroid 
research field has recently begun to embrace the use of molecular markers to help in 
making clinical decisions. For example, postoperative screening for the TERT promoter 
mutation in follicular tumors of uncertain malignant potential (FT-UMP) was found to 
inform follow-up and treatment, as the TERT mutation was a predictive marker of distant 
metastases (86). Further, current molecular testing does include the TERT promoter 
mutations in some platforms, including ThyroSeq® and ThyGenX®. Current guidelines, 
however, do not support using the TERT mutation status for initial risk stratification (87). 
In the new American Association of Endocrine Surgeons Guidelines for the Definitive 
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Surgical Management of Thyroid Disease in Adults, there is acknowledgement of 
inclusion of the TERT promoter mutation in assessment of the overall mutational burden 
in thyroid cancers (87). But for many molecular markers, the utility has not been tested 
given the newly published guidelines, nor has there been an incorporation of the new 
reclassification of the Non-Invasive Follicular Thyroid neoplasm with Papillary-like 
nuclear features (NIFTP). The 2015 American Thyroid Association Management 
Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer 
listed TERT, alone or in combination with BRAF, as potentially helpful to risk stratify 
patients in conjunction with other clinicopathological risk factors. However, this was 
considered a weak recommendation with low-quality evidence only (88).  
 
In conclusion, we know much about telomerase regulation. Capitalizing upon our deep 
understanding of these regulatory mechanisms may lead to crucial and needed therapeutic 
options in the future. Nevertheless, major gaps in our understanding of telomerase 
regulation remain. Understanding how TERT splicing is regulated is essential to a better 
understanding the activation of telomerase. Characterization of TERT promoter 
methylation as well as ETS transcriptional activator binding in thyroid cancer cell lines 
and patient samples is needed. Additionally, the study of chromosomal architecture 
surrounding TERT, and the effect of the TERT mutation on 3D chromatin structure in 
thyroid cancer have yet to be explored. One aspect that remains to be fully understood is 
how the higher levels of TERT expression and activity found in TERT-mutant cells 
provide a proliferative or other competitive advantage, since cancer cells typically have 
activated TERT expression to overcome the Hayflick limit long before TERT promoter 
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mutations arise.  Further understanding of how cancer cells that do not harbor the TERT 
mutation activate TERT through various regulatory methods still needs to be elucidated. 
Further studies are needed to determine the true utility of the TERT mutation status in a 






















Figure 1: An overview of TERT regulation in thyroid cancer.  
 
The landscape of the TERT promoter in thyroid cancer shows the TERT promoter 
mutation ( ), with hypermethylation ( ) further upstream of the TSS ( ). 
Transcriptional activators MYC and ETS family factors bind at the TERT promoter, the 
latter binding in the presence of the TERT mutation only. Alternative splicing of TERT in 
thyroid cancer. TERT is transcribed into mRNA, containing 16 exons (#5-9 shown). 

















Chapter 2: Telomerase Reverse Transcriptase Promoter 
Methylation and Transcription Factor Binding in 
Differentiated Thyroid Cancer Cell Lines 
Adapted from: Avin BA, et al. 2019 Characterization of human telomerase reverse 
transcriptase promoter methylation and transcription factor binding in differentiated 
thyroid cancer cell lines. Genes, Chromosom Cancer 58:530-540.  
Introduction 
TERT upregulation in cancer cells is multifaceted and complex. This transcriptional 
upregulation occurs via multiple mechanisms, including alteration of chromatin state, 
promoter hypermethylation, alternative splicing, and novel activator binding sites 
resultant from mutations (9–12). Previous work has characterized these various 
mechanisms of regulation in other cancer types, but not thyroid cancer. For this study we 
focused on characterizing promoter methylation patterns, transcription factor binding, 
and the resulting TERT transcription in thyroid cancer cell lines to better understand the 
interplay between TERT regulatory mechanisms.  
 
The TERT promoter is located in a 4 kb CpG island containing approximately 70% GC 
nucleotides, and exhibits a complex methylation pattern (see Figure 2) (46). The area 
surrounding the transcription start site (TSS) at -200 to +100 is typically unmethylated, 
and overlaps the “minimal promoter” at -260 to -75, which also encompasses the binding 
site for MYC. In contrast, further upstream of the TSS, at -650 to -200, the promoter is 
hypermethylated in telomerase positive cancer cells as compared to normal tissue. This 
hypermethylation pattern occurs in a multitude of cancer types, including prostate, 
medulloblastoma, gastric, esophageal, cervical, and colorectal cancer, and is caused by 
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currently unknown mechanisms (47, 48, 89, 90). The methylation status of the TERT 
promoter in thyroid cancer is currently unknown.  
 
TERT transcription can also be activated by promoter point mutations, supporting 
immortalization and tumorigenesis (17–19). These mutations are upstream of the 
translation start site, at -124C>T and -146C>T, respectively, relative to the ATG (20). 
Both TERT promoter mutations create a new consensus ETS factor binding site. 
Compared to the -146 C>T mutation, the -124 C>T mutation produces higher levels of 
TERT promoter transcriptional activation (26). At the -124 C>T mutation, the ETS 
transcription factor GABPA binds as a heterotetramer in multiple cancer types (26). 
Investigation into GABPA binding at the TERT promoter in thyroid cancer cell lines, 
which harbor the TERT mutation, has not been previously studied.  
 
In order to better understand the connection between promoter methylation and activation 
of telomerase, we performed tiled amplicon bisulfite sequencing followed by epiallele 
analysis. Analysis of epialleles, defined as distinctive patterns of methylation over a 
region of interest as captured in one sequenced amplicon, can allow for more biologically 
relevant interpretation, as CpG sites function collectively and not in isolation (91). We 
discovered a dual-methylation pattern at the TERT promoter in DTC cell lines, mirroring 
methylation patterns found in other telomerase positive cancers. Analysis of the 
hypermethylated upstream promoter led to discovering two putative activator binding 
sites by chromatin immunoprecipitation (ChIP). Additionally utilizing ChIP, we 
determined the enrichment of transcription factor binding at the TERT promoter in DTC 
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cell lines, and determined resulting TERT expression levels in these cells to further our 
understanding of the effect of TERT regulation on TERT activation.   
 
Results 
Targeted TERT promoter bisulfite sequencing 
DNA from all five DTC cell lines (see Supplemental Table 2 for BRAF & TERT mutation 
status) and six normal thyroid tissue samples was bisulfite treated, and the TERT 
promoter region, from –662 to +174 (relative to the transcription start site, TSS), was 
sequenced in three tiled amplicons. All CpGs in the targeted region had at least 60x 
coverage (Supplemental Figure 1), and any CpG site that was absent in more than two 
cell lines was removed from the analysis. The three biological replicates for each cell line 
were concordant, with a standard deviation of replicates (sd) ranging from 3.7-4.8%. The 
six normal thyroid tissue samples showed concordant methylation patterns as well (sd = 
4.69, see Supplemental Figure 2).  
 
TERT promoter methylation in papillary thyroid cancer cell lines 
We focused our attention on two human papillary thyroid cancer (PTC) cell lines, TPC-1 
and BCPAP. While TPC-1 is characterized as well differentiated, BCPAP is derived from 
a poorly differentiated PTC (92). Both PTC cell lines exhibited similar levels of 
methylation at the TERT promoter (Figure 3 and Supplemental Figure 3) with overall 
high levels of methylation in the sequenced portion of exon 1 (chr5:1,294,996-1,295,047) 
through just upstream of the TSS (1,295,162). Compared to PTC cell lines, normal 
thyroid tissue had the lowest methylation at each CpG within the entire region. The 
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CTCF binding site in exon 1 displayed methylation in the PTC cell lines, with no 
methylation in normal tissue. In the PTC cell lines, lower levels of methylation were seen 
upstream of the TSS for approximately 160 bases for the majority of the minimal 
promoter, including the area containing the ETS binding sites, with TPC-1 maintaining 
higher levels in this region compared to BCPAP. While the region further upstream, 
including the MYC binding site (1,295,339-1,295,800), was highly methylated in both 
PTCs (Figure 3), methylation was mostly absent until 177 bases upstream of the TSS for 
normal thyroid tissue. The more upstream region was partially methylated in normal 
tissue (see also epiallele analysis below). Both PTC cell lines and normal tissue showed a 
significant highly focal decrease in methylation at the upstream CpG at 1,295,547 
(illustrated by the arrowhead in Figure 3).  
 
TERT promoter methylation in follicular thyroid cancer cell lines 
Next, we characterized three human follicular thyroid cancer (FTC) cell lines, FTC-133, 
FTC-238, and WRO (Figure 4 and Supplemental Figure 3). FTC-133 and FTC-238 
originate from the same patient at different time points and disease stages (93), where 
FTC-133 is a local lymph node metastasis and FTC-238 is a late distant hematogenous 
metastasis. WRO is derived from a metastasis from another FTC patient, and is the only 
DTC cell line analyzed here that does not harbor an activating TERT promoter mutation. 
As in PTC, all three FTC cell lines showed higher levels of methylation at each CpG than 
normal tissue. Of the three FTC cell lines, FTC-133 showed the least amount of 
methylation overall, although it exhibited a pattern similar to FTC-238 (Figure 4). While 
WRO mirrored the methylation pattern of the other FTC cell lines upstream of 1,295,339, 
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it had much higher levels of methylation in the areas surrounding the TSS and 
downstream into exon 1 compared to the other two FTC cell lines. The only region of the 
TERT promoter that was not highly methylated in WRO occurred at 1,295,225-1,295,248, 
less than a hundred bases upstream of the TSS (Figure 4), and this unmethylated region 
contains the mutation-created ETS binding sites in other DTC cell lines, which are absent 
in WRO. The drop in methylation at CpG 1,295,547, observed in PTC cell lines, was also 
noted in FTC cell lines FTC-133 and FTC-238, but not in WRO. Also concurrent with 
PTC cell lines, FTC cell lines showed partial methylation at the MYC and CTCF binding 
sites. 
 
Differential methylation between FTC-133 and FTC-238 
Studying FTC-133 and FTC-238 provided a direct comparison between early local 
lymphatic (FTC-133) and later-originating distant hematogenous (FTC-238) thyroid 
cancer metastases. An analysis of differentially methylated regions (DMRs) within the 
TERT promoter revealed nine DMRs of varying lengths between the two FTC cell lines 
(Figure 5 and Supplemental Table 1). Overall, FTC-133 was hypomethylated compared 
to FTC-238 (Figure 5A). The largest DMR, from 1,295,017-1,295,155, ranges from the 
5’ untranslated region into exon 1 of TERT and exhibited significantly more methylation 
in the distant metastasis, than the lymph node metastasis (Figure 5A, B).  
 
Epiallelic characterization of MYC binding site 
Methylation levels at the MYC binding site at the TERT minimal promoter in DTC cell 
lines were approximately 50% for all cell lines, with the exception of FTC-133, which 
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showed less methylation and more closely mirrored normal thyroid methylation (Figure 
6). MYC has been shown to bind in an allele specific manner when there is a methylation 
difference between the two alleles (94, 95), which may be the case at the TERT promoter. 
Therefore, epiallele analysis for the MYC minimal promoter binding site was conducted. 
This analysis revealed a methylation pattern where about half the reads were fully 
methylated and the other half fully unmethylated across CpGs at the binding site (Figure 
7), pointing to potential allele specific methylation patterns that may affect MYC binding 
at the TERT locus. This pattern was seen in all DTC cell lines except for the early disease 
stage cell line FTC-133, which, demonstrated predominantly unmethylated CpGs, similar 
to normal thyroid tissue.  
 
Epiallelic characterization of TERT upstream promoter 
The upstream promoter region, covering 1,295,587 to 1,295,800, was partially or fully 
methylated at every CpG in all DTC cell lines. As this area has been shown to be 
characteristically highly methylated in other cancers (13), epiallele analysis was 
conducted to examine this area further. While in Figure 6, the upstream region of normal 
thyroid tissue appears partially methylated, epiallele analysis displays the region being 
mostly unmethylated. Examining the frequency of single allele methylation, the most 
common pattern across the upstream TERT promoter region in normal tissue shows all 
CpGs unmethylated in 75% of reads (Figure 8). In contrast to normal tissue, the most 
prominent epialleles in WRO, FTC-238, and TPC-1 show the upstream region fully 
methylated, while in FTC-133 and BCPAP, the most common epialleles exhibited foci of 
unmethylated CpGs. Interestingly, and with potential biological relevance, the CpG site 
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at 1,295,686 showed a marked focal drop in methylation to very low levels, across all 
DTC cell lines with the exception of WRO, as well as in normal tissue. Other sites, such 
as 1,295,649-1,295,651, exhibit an unmethylated pattern in PTC cell lines TPC-1 and 
BCPAP, while the surrounding CpGs are methylated, also pointing to potentially 
biologically relevant sites. 
 
Motif analysis of upstream TERT promoter 
Epiallele analysis of the upstream TERT region showed conserved sites of focal lower 
methylation (Figure 8). A review of transcription factors known to bind this area (96) 
showed no known factors. Therefore, we conducted motif analysis using the MEME 
Suite (97) at the 1,295,649-1,295,651 site and at the focal methylation drop at 1,295,547. 
Motif analysis revealed a potential E-box binding site encompassed in 1,295,649-
1,295,651. The TERT sequence ‘CCGCGTG’ is identical except one base pair to the 
MYC consensus sequence ‘CCACGTG’. The 1,295,547 drop in methylation was 
identified to contain a putative Goosecoid Homeobox (GSC) motif. The consensus 
sequence for GSC is ‘TAATCC’, and the TERT sequence is ‘TAACCC’, a one base pair 
mismatch. This suggests GSC may bind at the TERT promoter.  
 
Transcription factor binding at the TERT promoter in DTC cell lines and normal 
thyroid tissue 
Binding of known and predicted transcription factors at the TERT promoter was 
measured. Chromatin immunoprecipitation with a CTCF-specific antibody showed 
variable binding at the CTCF binding site at TERT in all cell lines, while CTCF did not 
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exhibit binding in normal thyroid tissue (Figure 9A). Transcription factor GABPA was 
probed by ChIP (Figure 9B), and cell lines BCPAP and WRO had minimal binding 
compared to TPC-1, FTC-133, and FTC-238. These three cell lines with increased 
GABPA binding all harbor TERT promoter mutations creating the GABPA binding site. 
TPC-1 and FTC-238 harbor the -124 C>T mutation heterozygously, while FTC-133 is 
homozygous for the mutation. As expected, normal thyroid tissue showed minimal 
binding of GABPA at the TERT promoter. In probing for MYC binding (Figure 9C), two 
regions were interrogated by PCR amplification. The MYC binding site in the minimal 
promoter showed binding in the TPC-1 and FTC-133 cell lines, as well as in normal 
thyroid tissue. MYC binding in FTC-133 and in normal tissue was expected due to the 
low levels of methylation, but overall, methylation status did not correlate closely with 
MYC binding. The potential E-box binding site upstream identified by motif analysis 
also showed binding of MYC, particularly in the least methylated FTC-133 and normal 
tissue samples, while all other DTC cell lines exhibited a lesser degree of binding in the 
upstream region (Figure 9C). Lastly, GSC ChIP was conducted for the identified focal 
drop in methylation at the 1,295,547 site in the upstream TERT region. GSC showed 
binding relative to input at the upstream TERT promoter proposed GSC binding site in all 
DTC cell lines and normal thyroid tissue (Figure 9D), with the two papillary thyroid 
cancer cell lines exhibiting the largest amount of binding.  
 
TERT expression in DTC cell lines and normal tissue 
TERT transcript levels were measured by quantitative RT-PCR, in triplicate and with two 
biological replicates, to measure TERT expression in the DTC cell lines and normal 
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thyroid tissue. As shown in Figure 10, all DTC cell lines exhibited variable amounts of 
TERT expression, while normal thyroid tissue did not express TERT. WRO showed the 
lowest TERT expression, while FTC-238 exhibited the highest TERT levels.  
 
Discussion 
While TERT promoter methylation patterns have been characterized in various cancer 
types, only one study has explored the TERT promoter methylation pattern in thyroid 
cancer. In that study, only 8 CpGs spanning 37 base pairs in medullary thyroid cancer 
was studied in 38 tumors (16). Herein, we interrogated TERT promoter methylation 
patterns in a much larger region (chr5:1,294,996/+166 - 1,295,800/-638) in papillary 
thyroid cancer cell lines TPC-1 and BCPAP, and in follicular thyroid cancer cell lines 
WRO, FTC-133, and FTC-238, and in normal thyroid tissue. We also characterized 
transcription factor binding and TERT expression to explore the relationship between 
promoter methylation and transcriptional activation. 
 
Our characterization of the TERT promoter by bisulfite amplicon sequencing revealed 
that DTC cell lines exhibit the dual-methylation pattern commonly observed in other 
telomerase positive cancer cell types (13), including medullary thyroid cancer (16), i.e., 
low levels of methylation in the minimal promoter near the TSS, while the region further 
upstream was highly methylated. This upstream region of hypermethylation has been 
shown to be tightly correlated with TERT expression, activation of telomerase, and worse 
clinical outcomes, and is used as a biomarker in pediatric brain tumors and melanoma, 
specifically with methylation of the region 1,295,647-703 serving as a prognostic marker 
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for tumor progression and poor prognosis (89). Whereas the lack of methylation at the 
TSS was similar between normal thyroid tissue and cancer cells, the hypermethylation of 
only the upstream TERT promoter in cancer may be key to transcriptional activation of 
TERT. Absence of methylation within the minimal promoter has been correlated with 
higher levels of TERT transcription (48, 98), but our results suggest a more complex 
relationship between minimal promoter methylation and transcriptional activity. 
Comparison of the two FTC cell lines obtained from the same patient at different stages 
of the disease revealed that the region spanning the 5’UTR to exon 1 exhibited higher 
levels of methylation in the later distant metastasis-derived line, which also exhibited 
much higher levels of TERT expression than the earlier local lymph node metastasis-
derived line with lower levels of methylation. This seems counterintuitive to the 
conventional expectation that higher DNA methylation levels at the TSS decrease gene 
expression and suggests a role of areas outside of the minimal promoter in activating 
TERT.  
 
We also considered the binding sites for MYC and CTCF proximal to the TSS, an 
activator and repressor for TERT, respectively (98), which may also play important roles 
in activation of TERT. In normal thyroid tissue, the CTCF binding site was unmethylated, 
however the factor did not exhibit binding in normal thyroid tissue by ChIP-qPCR, while 
in all DTC cell lines, the CTCF site was at least partially methylated, and all DTC cell 
lines showed binding of CTCF. As methylation has been shown to block binding of 
CTCF to TERT, further examination of CTCF binding at the TERT promoter is needed 




Interestingly, the binding site for MYC within the minimal promoter was also partially 
methylated in all DTC, as well as normal thyroid tissue. However, hypermethylation in 
telomerase positive tumor tissue and cell lines at the MYC binding site has been observed 
previously (101). Through epiallele analysis, it was found that the MYC binding site may 
be fully methylated in one allele, and fully unmethylated on the other allele- except for in 
FTC-133 and normal thyroid tissue, which are predominantly unmethylated. ChIP 
analysis showed that FTC-133, TPC-1, and normal tissue exhibited binding of MYC at 
the minimal promoter. The low levels of methylation at the site in FTC-133 and normal 
tissue agree with MYC binding. However the partial methylation at TPC-1 warrants 
further studies to evaluate its role in activation, possibly in an allele-specific fashion, and 
its binding in normal tissue suggests MYC may be necessary, but not sufficient, to 
activate transcription. 
 
The WRO cell line exhibited high levels of methylation throughout the entire TERT 
promoter region, except at the ETS binding sites. The cell line also exhibited the lowest 
level of TERT transcription of the DTC cell lines. WRO may be activating telomerase via 
a different, less robust mechanism, in which its mutational background may play a role. 
WRO is also unusual in harboring the BRAF activating heterozygous mutation, which is 
more typical of PTC than FTC. The significance of overexpression of the GABPA factor 
by BRAFV600E mutation without a TERT promoter mutation is currently unknown. 
WRO did exhibit low GABPA binding, which is consistent with a lack of binding site in 
the absence of a TERT mutation. BCPAP also exhibited minimal binding of the factor, 
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which may be due to the unique TERT mutation status it carries, with -124/-125 CC>TT, 
which does not perfectly create the consensus sequence needed for GABPA to bind. The 
cell lines FTC-133 and TPC-1 showed the most GABPA binding by ChIP-qPCR, and 
FTC-133 is the only cell line tested which is homozygous for the mutation, while TPC-1 
is heterozygous for the TERT mutation. The other TERT heterozygous mutant, FTC-238, 
showed intermediate levels of GABPA binding.  
 
The investigation of focal changes in methylation in the hypermethylated upstream 
region allowed the identification of two additional potential activating sites, a putative E-
box and a GSC binding site. This upstream E-box binding site showed binding of MYC 
in all cell lines, with a high amount of binding in FTC-133 and normal thyroid tissue, 
which also had the lowest levels of methylation at this binding site. This site may be 
important for activation, as it is less densely methylated than the surrounding CpGs.  
 
Our motif analysis also identified a GSC factor binding site in the upstream TERT 
promoter, which was less methylated than surrounding CpGs in all cell lines except 
WRO. ChIP analysis of GSC showed binding of the factor at the upstream TERT 
promoter, with normal thyroid tissue and the two FTC cell lines FTC-133 and FTC-238 
showing the least GSC binding. Furthermore, COSMIC data show overexpression and 
copy number variations of GSC in thyroid cancer (102), which may point to other 
mutations necessary for activation of GSC. GSC has been shown to be oncogenic in 
ovarian carcinoma, where overexpression of TERT and GSC resulted in chemoresistance 
and poorer prognosis (103). GSC has also been shown to promote epithelial-
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mesenchymal transition in numerous cancers including prostate, breast, and 
hepatocellular carcinoma (104–106). These findings suggest that further exploration into 
GSC as an activator of TERT is warranted. 
 
In summary, we have characterized the dual-methylation pattern at the TERT promoter in 
DTC cell lines. This pattern mirrors other telomerase positive cancer cell lines, and 
shows a dysregulation in methylation compared to normal thyroid tissue. Specifically, the 
upstream TERT promoter is hypermethylated in cancer, which may be important for 
transcriptional activation of TERT, and we identified two putative activator binding sites 
in the upstream region. While the minimal promoter shows variable levels of methylation 
between DTC cell lines, overall there is a lack of methylation, as seen in normal tissue. 
The methylation state of the minimal promoter may therefore not play a determining role 
in TERT re-activation. Lastly, TERT promoter mutations may cause allele-specific 
methylation changes at the minimal promoter and affect transcription factor binding, 
which can be influenced by additional activating mutations. As we observed no simple 
correlation between promoter methylation status and transcript levels, future work needs 
to be done to establish a causative role of TERT promoter methylation affecting 























































































































1294996 1294996 1 1 3.26 3.26 3.26 0.14 0.48 0.34 0.04 hyper 






0.33 0.58 0.05 hypo 




0.21 0.45 0.05 hypo 
1295279 1295279 1 1 1.45 1.45 1.45 0.08 0.16 0.09 0.05 hyper 
1295339 1295377 39 5.57 -25.54 -0.65 -
3.09 
-0.2 0.3 0.49 0.05 hypo 




0.3 0.48 0.06 hypo 
1295445 1295491 47 4.7 -35.53 -0.76 -
2.96 
-0.2 0.28 0.48 0.06 hypo 




0.44 0.64 0.05 hypo 
1295762 1295772 11 5.5 3.93 0.36 2.5 0.1 0.84 0.74 0.05 hyper 
a Differentially methylated region, binvdensity= average length in bp per CpG, cDMR.Area.Tstat = 
sum of the T-statistics of the individual methylation loci, dDMR.Avg.Tstat = length independent 
metric of the Tstat for each DMR, eMax.Tstat = the maximum T-statistic for an individual CpG, 
fMean.Difference = the mean difference in methylation loci, gstandard deviation, hdirection of 













Table S2: Mutation status of thyroid cancer cell lines by Sanger sequencing for the BRAFV600E 
mutation and the TERT promoter mutations 

























TPC-1 Well differentiated 
papillary 
WT -124 C>T heterozygous 
mutant 












Follicular (lymph node 
metastasis)a 










Figure 2: TERT promoter methylation 
 
Methylation pattern relative to the transcription start site (TSS) in either cell lines (CL) or 
patient blood/tumor samples (PS) with positive telomerase expression given in black and 
white rectangles, with black denoting hypermethylated regions and white denoting 
hypomethylated regions. Cancer abbreviations are: breast (BRCA), lung (LUN), colon 
(COL), cervical (CES), acute myeloid leukemia (AML), hepatocellular carcinoma 
(HCC), acute promyelocytic leukemia (APL), bladder (BLA), and glioblastoma (GBM). 
Transcription factor binding sites for MYC, ETS, and CTCF are shown, with the minimal 
promoter represented by a dashed arrow, and TERT promoter mutations indicated by *. 
The proximal MYC site is shaded to denote a lesser importance in transcriptional 
activation. The translation start site is depicted by a dashed arrow head. The amplicons 

















Figure 3: Characterization of TERT promoter methylation by bisulfite sequencing 
in papillary thyroid cancer cell lines compared to normal thyroid tissue 
 
The overall % methylation level at each CpG site over the TERT promoter region 
(chr5:1,294,996/+166 to 1,295,800/-638) in papillary thyroid cancer cell lines TPC-1 
(blue) and BCPAP (red), compared to normal thyroid tissue (green). Colored lines 
represent the average methylation % levels for both TPC-1 and BCPAP. Biological 
triplicates are represented in different colored dots. Transcription factor binding sites 
(boxes below), the minimal promoter region (dashed line), the TERT promoter mutations 
(*), methylation drop (arrowhead), and the transcription start site (solid arrow) and 













Figure 4: Characterization of TERT promoter methylation in follicular thyroid 
cancer cell lines compared to normal thyroid tissue 
 
The overall methylation level per CpG locus, as a percentage, over the TERT promoter 
region chr5:1,294,996 (+166) to 1,295,800 (-638) bisulfite sequenced in follicular thyroid 
cancer cell lines WRO, FTC-133, and FTC-238 compared to normal thyroid tissue. The 
line represents the average methylation % levels for each cell line. Biological triplicates 
are represented in different colored dots. Transcription factor binding sites (boxes below), 
the minimal promoter region (dashed line), the TERT promoter mutations (*), 
methylation drop (arrowhead), and the transcription start site (solid arrow) and translation 












Figure 5: Significant differentially methylated regions between cell lines established 
from the same patient, at different metastatic locations 
 
A) Adapted Integrative Genomics Viewer (IGV) visualization of the TERT promoter 
region (build hg19), with black arrows showing the direction of transcription and 
translation of TERT. Line graph illustrates the percentage of methylation per CpG over 
the region in the lymph node metastasis (FTC-133) and distant metastasis (FTC-238) 
follicular thyroid cancer cell lines. Differentially methylated regions (DMRs), as 
determined by the R package bsseq, are defined by blue (distant metastasis is 
hypomethylated relative to lymph node) or red (distant metastasis is hypermethylated 
relative to lymph node) blocks covering the DMR between the two cell lines. B) 
Representative plot of the methylation per CpG over an identified DMR region for the 
differing cell lines, in triplicate. CpGs are represented by tick marks along the x-axis, and 







Figure 6: Overall TERT promoter methylation pattern in differentiated thyroid 
cancer cell lines compared to normal thyroid tissue 
 
Depiction of the TERT promoter from +166 to -638 (relative to the transcription start site) 
with transcription factor binding sites (CTCF, MYC, ETS), the promoter mutations 
illustrated by *, and the minimal promoter highlighted at their respective locations. Each 
cell line tested, along with normal thyroid tissue (Normal), is listed in the leftmost 
column. Each CpG site is represented as a column, with chromosomal location listed 
above, in which methylation is a gradient, with blue indicating low levels of methylation, 
















Figure 7: Epiallele analysis of MYC binding site in TERT promoter 
 
Epiallelic characterization of the TERT promoter conducted by MethPat analysis 
depicting epialleles for the MYC binding region 1,295,339-1,295,353. Each column in 
the plot is an individual CpG, where the proportion of methylation at each CpG is shown, 
with methylated CpGs (black) and unmethylated CpGs (white). The amount of reads with 
a given methylation pattern for all CpGs in the read are shown in order of the most 

















Figure 8: Epiallele analysis of upstream TERT promoter hypermethylation in DTC 
 
Epiallelic characterization of the TERT promoter conducted by MethPat analysis 
depicting epialleles for the upstream TERT region 1,295,587-1,295,800. Each column in 
the plot is an individual CpG, where the proportion of methylation at each CpG is shown, 
with methylated CpGs (black) and unmethylated CpGs (white). The amount of reads with 
a given methylation pattern for all CpGs in the read are shown in order of the most 















Figure 9: Transcription factor binding varies at the TERT promoter in DTC cell 
lines and normal thyroid tissue 
 
Binding was measured relative to 5% input chromatin, and binding at the TERT locus 
normalized to a positive control locus for each factor in the indicated cell lines and 
normal thyroid tissue by ChIP-qPCR for A) CTCF, B) GABPA, C) MYC, at two 
positions- the minimal promoter binding site and the upstream binding site, D) GSC. All 















Figure 10: TERT transcript level in thyroid cancer cell lines and normal thyroid 
tissue 
 
TERT transcript level was assessed by quantitative RT-PCR in thyroid cancer cell lines 
and six normal thyroid tissue samples (averaged together). TERT expression was 

















Figure S1: Read coverage of amplicon bisulfite sequencing of the TERT promoter 
 
Coverage shown in natural log scale over chr5:1,294,996 to chr5:1,295,800 (hg19 build) 
in each of the samples. Where in all cancer cell lines (TPC-1, BCPAP, WRO, FTC-133, 
FTC-238) samples 1-3 are biological replicates. Normal thyroid tissue (Normals) are six 
different tissue samples. SNPs were filtered on the criteria described in the Methods, and 




















Figure S2: Characterization of TERT promoter methylation in normal thyroid 
tissue by bisulfite sequencing 
 
The overall methylation level per CpG locus, as a percentage, over the TERT promoter 
region chr5:1,294,996 (+166) to 1,295,800 (-638) bisulfite sequenced in patient samples 
from six normal thyroid tissues. Each patient sample is represented in a different color 













Figure S3: Characterization of TERT promoter methylation by bisulfite sequencing 
in differentiated thyroid cancer cell lines  
 
The overall % methylation level at each CpG site over the TERT promoter region 
(chr5:1,294,996/+166 to 1,295,800/-638) in papillary thyroid cancer cell lines TPC-1 (A), 
BCPAP (B), and follicular thyroid cancer cell lines WRO (C), FTC-133 (D), and FTC-
238 (E). Biological triplicates are represented in different colored dots numbered 1-3, 
with the average of the triplicates shown by the black line, and a red dashed line for the 















Figure S4: Transcription factor binding varies at the TERT promoter in DTC cell 
lines 
 
Binding was measured relative to 5% input chromatin in the indicated cell lines by ChIP-
qPCR for (A) CTCF. The HBB locus was used as a positive control, and the H19 exon 
junction as a negative control for CTCF binding, (B) MYC. The APEX1 locus was used 
as a positive control, and ALB as a negative control, (C) GABPA. The RACGAP1 locus 
was used as a positive control, and ALB as a negative control, (D) GSC. The GSC2 locus 
was used as a positive control, and GAPDH as a negative control. All error bars represent 














Figure S5: Transcription factor binding varies at the TERT promoter in normal 
thyroid tissue 
 
Binding was measured relative to 5% input chromatin in six normal thyroid tissue 
samples indicated by #1-#6 by ChIP-qPCR for (A) CTCF. The HBB locus was used as a 
positive control, and the H19 exon junction as a negative control for CTCF binding, (B) 
MYC. The APEX1 locus was used as a positive control, and ALB as a negative control, 
(C) GABPA. The RACGAP1 locus was used as a positive control, and ALB as a negative 
control, (D) GSC. The GSC2 locus was used as a positive control, and GAPDH as a 















Chapter 3: Allele-Specific Regulation of Telomerase Reverse 
Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines 
Adapted from: McKelvey BA, et al. 2020 Characterization of Allele-Specific Regulation 
of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines. 
Thyroid Published Online thy.2020.0055. 
Introduction 
Previously, we characterized TERT promoter methylation, transcription factor binding, 
and their relationship to TERT promoter mutations in thyroid cancer cell lines (107). 
Specifically, we identified a unique methylation pattern suggesting allele-specific 
methylation in heterozygous TERT mutant thyroid cancer cell lines. It is believed that 
different types of regulation can work in concert and modulate each other’s effects on 
transcription (108). Herein, we investigate the allele-specific effects of TERT promoter 
mutations on promoter methylation, transcription factor binding, chromatin marks, and 
transcriptional activation.  
 
TERT promoter methylation may play a key regulatory role, including inhibition of 
transcription factor binding and changing of chromatin state (38, 39, 109). In other 
genomic locations, DNA methylation blocks binding of the transcriptional activator 
MYC (95), which also binds to the TERT minimal promoter to activate TERT 
transcription (110). Our previous work demonstrated binding of MYC at the minimal 
TERT promoter, and methylation patterns in heterozygous TERT mutant thyroid cancer 
cell lines in of about 50% methylation (107). This suggested that allele-specific 
methylation in heterozygous mutant cell lines might play a role in regulation. In support 
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of this, TERT mutant cancers were recently shown to display lower levels of methylation 
at the TERT promoter than wildtype cancers (56). However, allele-specific methylation at 
the TERT promoter, or allele-specific binding of MYC to TERT has not been shown. This 
is in part because standard methylation sequencing has mostly been performed in the 
context of sodium bisulfite pretreatment of DNA, which reverts both TERT promoter 
mutations back to wild type (C->T). New nanopore sequencing technology (111) relies 
on Cas9 targeting and cutting at specific genomic locations, allowing for targeted long 
read sequencing. Unlike Illumina sequencing based on florescence, nanopore sequencing 
detects nucleotide-specific changes in ionic current as a single molecule of DNA moves 
through a protein pore inserted into a synthetic polymer membrane (112). Importantly, 
nanopore sequencing can distinguish cytosine from methyl-cytosine, negating the need 
for sodium bisulfite pretreatment of DNA. This profiles DNA methylation at the targeted 
sequence directly, thus enabling one to assess methylation in an allele-specific manner 
over a much larger genomic region than previously possible.  
 
Further, a subset of cancer cell lines appear to show monoallelic expression (MAE) of 
TERT from the TERT mutant promoter (55). Studies have identified heterozygous SNPs 
in the TERT coding region and demonstrated only one allele in the TERT cDNA 
transcript (52, 56). However, since the TERT promoter mutation is not represented in the 
coding sequence, studies have not definitively linked the TERT promoter mutation with 




In this study, we definitively demonstrate for the first time allele-specific methylation at 
the TERT promoter and into the gene body, in which the mutant allele is significantly less 
methylated at the TERT promoter than the wildtype allele, and more methylated into the 
gene body than the wildtype allele, consistent with the methylation pattern of actively 
transcribed genes (113, 114). We utilized chromatin immunoprecipitation followed by 
Sanger sequencing to confirm allele-specific binding of GABPA to the mutant TERT 
allele in thyroid cancer cell lines, and demonstrate for the first time similar allele-specific 
binding of MYC. Furthermore, we show chromatin marks associated with active 
transcription (H3K4me3) on only the mutant allele, while repressive chromatin marks 
(H3K27me3) associate with the wildtype allele. The allele-specific TERT promoter 
methylation, differential histone modifications, and activator binding, all result in 
monoallelic expression, the latter demonstrated by phasing a SNP present in exon 2 of 
TERT with the allele carrying the TERT promoter mutation. In summary, we report the 
first direct evidence of monoallelic expression by the TERT promoter mutation, and 
confirm previous findings in other cancer types of allele-specific binding of GABPA and 
chromatin marks in thyroid cancer cell lines.  
 
Results 
Allele-Specific Methylation Patterns in Thyroid Cancer Cell Lines  
DNA isolated from thyroid cancer cell lines underwent enrichment and nanopore 
sequencing at the TERT promoter by nCATS to determine the methylation status of the 
TERT promoter. Nanopore methylation calls for all cell lines were compared and found 
comparable to previously published Illumina bisulfite sequencing of the TERT promoter 
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(107) (Supplemental Figure 7). Unlike traditional bisulfite treatment, in which the TERT 
mutation status (C>T) is lost, nanopore sequencing identifies native methylation without 
bisulfite treatment and thereby maintains the ability to differentiate mutation status 
between alleles. In the heterozygous TERT mutant cell line TPC-1, a significant drop in 
methylation surrounding the TERT TSS occurred on the mutant allele, to under 5% 
methylation (Figure 11). The mutant allele also showed higher levels of methylation 
throughout the TERT gene body at or above 75%, while the wildtype allele remained 
comparatively stable at approximately 50-75% methylation over the TERT gene body and 
promoter. The other heterozygous TERT mutant cell lines BCPAP and FTC-238 followed 
the same pattern as TPC-1, in which there was a drop in methylation at the TSS with only 
20% and 30% of the mutant allele methylated in BCPAP and FTC-238 respectively 
(Figure 12, Supplemental Figure 8). The heterozygous mutant cell lines also exhibited the 
higher levels of methylation in the gene body. In BCPAP, a drop in methylation in the 
wildtype allele was observed in the gene body, specifically in the intron between exon 2 
and 3. The homozygous TERT mutant cell line FTC-133 showed a methylation pattern 
consistent with the mutant alleles of the heterozygous cell lines, showing a drop in 
methylation to less than 15% at the TSS and high gene body methylation. Conversely, the 
homozygous wildtype cell line WRO showed no significant drop in methylation at the 
TSS (above 50%) and lower levels of 50-75% methylation in the gene body, reflective of 
the wildtype alleles in the heterozygous mutant cell lines (Figure 12). Further 
examination of TERT promoter methylation revealed low methylation surrounding the 
transcription start site (TSS) in the mutant allele (4.8%, 20%, 31.8% average methylation 
for TPC-1, BCPAP, and FTC-238 respectively), while high levels of methylation were 
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seen in the wildtype allele (Figure 13) (79.9%, 73.1%, 75.1% average methylation for 
TPC-1, BCPAP, and FTC-238 respectively). Furthermore, the regions surrounding the 
TERT promoter mutation at the GABPA binding site, as well as the MYC binding site, 
also exhibited significantly less methylation on the mutant allele, with the exception of 
the GABPA site in FTC-238, which exhibited low methylation of both alleles. 
Homozygous cell lines followed similar patterns of methylation, with the homozygous 
mutant cell line exhibiting low levels of methylation at the promoter (less than 20% 
methylation), and the homozygous wildtype cell line showing higher levels of 
methylation (30-65% methylation) (Figure 13).  
 
Allele-Specific Transcription Factor Binding in Thyroid Cancer Cell Lines 
Since the binding sites for GABPA and MYC were differentially methylated in our 
heterozygous mutant thyroid cancer cell lines, we investigated whether these factors 
exhibited allele-specific binding as well. ChIP analysis of the two ETS factors known to 
bind at the TERT promoter, ETV5 and GABPA, showed GABPA as the predominant 
factor binding to the TERT promoter in our well differentiated thyroid cancer cell lines 
(Supplemental Figure 9). We therefore performed Sanger sequencing of the TERT 
promoter on DNA precipitated with either MYC or GABPA antibodies. Sanger 
sequencing of immunoprecipitated DNA from TPC-1, BCPAP, and FTC-238 cell lines 
resulted in only the mutant TERT allele, indicating selective binding of GABPA and 
MYC to the mutant allele (Figure 14).  
 
Allele-Specific Chromatin Marks in Thyroid Cancer Cell Lines 
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To further investigate transcriptional regulation, ChIP followed by Sanger sequencing of 
the region of the TERT promoter encompassing the TERT mutation and TSS, was 
conducted on DNA immunoprecipitated with antibodies directed against either H3K4me3 
(activating) or H3K27me3 (silencing). This revealed the least amount of active chromatin 
mark, H3K4me3, in the wildtype cell lines Nthy-ori-3 and WRO, an intermediate amount 
in the heterozygous TERT mutant cell lines (TPC-1, BCPAP, and FTC-238), and the 
highest amount associated with the homozygous TERT mutant cell line FTC-133 (Figure 
15A). The silent chromatin mark, H3K27me3, displayed the opposite trend, with the 
highest level in the homozygous wildtype cell lines, and the least abundant in the 
homozygous TERT mutant cell line. To further delineate the effect of the TERT mutation 
on chromatin marks, we conducted Sanger sequencing of the immunoprecipitated DNA 
at the TERT locus. In the heterozygous TERT mutant cell lines, we observed an allele-
specific association with chromatin marks. The TERT mutant allele preferentially bound 
to the active H3K4me3, while the wildtype allele bound to the silent H3K27me3 (Figure 
15B).   
 
Monoallelic Expression of TERT  
To determine if monoallelic expression of TERT occurs in our heterozygous TERT 
mutant thyroid cancer cell lines, we identified SNPs in the TERT coding sequence. As 
previously described (29), TPC-1 contains a heterozygous G>A SNP in exon 2 
(rs2736098). In the heterozygous cell lines BCPAP and FTC-238, a C>T SNP 
(rs2853690), was identified in the TERT 3’UTR by Sanger sequencing of the genomic 
DNA (Figure 16). Sanger sequencing of cDNA from all three cell lines showed 
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transcripts with only one of the SNP alleles, confirming monoallelic TERT expression 
(Figure 16). Furthermore, through long sequencing reads obtained by nCATS, we 
confirmed the TERT promoter mutation to be on the same allele as the expressed 
transcript of exon 2 in TPC-1. This expression of only the ‘A’ allele at exon 2 
(rs2736098) in TPC-1 directly confirms expression of TERT only from the mutant TERT 
allele.  
 
Transcriptional Output and Telomerase Activity  
To characterize overall telomerase activation, we measured full length TERT transcripts, 
in which the alpha nor beta regions were present, in our thyroid cancer cell lines by 
quantitative reverse transcriptase PCR (qRT-PCR). We observed that the wildtype 
normal thyroid cell line, Nthy-ori-3, had no measurable amount of full length TERT 
transcript, and the wildtype WRO showed the least amount of transcript of the cancer cell 
lines (Figure 17). Interestingly, FTC-133, the homozygous TERT mutant thyroid cancer 
cell line, exhibited less TERT transcript than the three heterozygous TERT mutant thyroid 
cancer cell lines. This pattern also correlated with relative telomerase activity (RTA), in 
which FTC-133 also showed less telomerase activity than the three heterozygous TERT 
mutant cell lines. The wildtype cell lines showed the least telomerase activity. 
 
Discussion 
It is already known that TERT promoter mutations activate TERT transcription and 
telomerase activity. However, due to limitations in sequencing technology, the allele-
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specific effects of the heterozygous TERT promoter mutation have not been completely 
elucidated. Utilizing thyroid cancer cell lines that harbor the TERT mutation (11), and 
nanopore Cas9 targeted sequencing (nCATS), we demonstrated allele-specific 
methylation at the TERT promoter and into the gene body. Specifically, we used ChIP-
Sanger sequencing to show both allele-specific GABPA and MYC binding, and allele-
specific distribution of both active and silent histone modifications (H3K4me3 and 
H3K27me3). These allele-specific effects correlated directly with monoallelic expression 
of TERT in the heterozygous TERT mutant cell lines as well as overall higher levels of 
TERT transcription and telomerase activity.  
 
Our characterization of TERT promoter methylation in thyroid cancer cell lines revealed 
significantly lower methylation levels at the transcription start site (TSS), TERT mutation 
site, and MYC binding site on the TERT mutant allele compared to the wildtype allele. 
These findings corroborate previous work that showed overall lower levels of TERT 
promoter methylation in TERT mutant cancer cell lines (56). Importantly, however, our 
study extends the work by examining methylation patterns on non-amplified DNA in an 
allele-specific manner. This demonstrated that only the mutant allele is hypomethylated, 
with a significant dip (less than 30% methylated in the mutant allele compared to over 
70% methylated in the wildtype allele) in methylation restricted to the TSS, and thus, 
demonstrating for the first time allele-specific methylation of TERT. The homozygous 
wildtype and homozygous TERT mutant cell lines follow the same methylation pattern as 
the heterozygous alleles. This pattern of promoter hypomethylation and gene body 
methylation is in line with previously reported methylation patterns for genes with active 
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transcription (113–115). Further, our studies of histone modifications support the 
activation of the TERT mutant allele, as the mutant promoter was associated with 
activating H3K4me3 marks, while the wildtype allele exhibited silencing H3K27me3 
marks, a pattern also seen in other cancer cell types (52).  
 
The TERT promoter mutation (-124 C>T) creates a consensus binding site for the ETS 
family factors, and we previously demonstrated the factor GABPA bound to the TERT 
promoter in our cell lines derived from well-differentiated thyroid cancers (107). After a 
recent study described ETV5 binding at the TERT promoter in thyroid cancer cell lines 
(29), we investigated ETV5 binding in our thyroid cancer cell lines. We found that ETV5 
bound significantly less at the TERT promoter than GABPA in our thyroid cancer cell 
lines. The recent paper functionally characterized ETV5 in three thyroid cancer cell lines, 
two derived from anaplastic thyroid cancers and one derived from papillary thyroid 
cancer, finding that ETV5 predominantly bound in the two anaplastic thyroid cancer cell 
lines, while the papillary thyroid cancer cell line, TPC-1, showed GABPA binding (29). 
Our GABPA results confirm their findings in TPC-1, and further defines   ETS factor 
involvement in well differentiated thyroid cancer. ETV5 and a different regulatory 
mechanism may be present in less differentiated cancer cells.  
 
We have confirmed, as seen in other cancer types (26, 52), that GABPA binds to the 
TERT mutant allele in an allele-specific manner in thyroid cancer cell lines. Our previous 
work showed the highest level of GABPA binding in the TERT homozygous mutant, with 
moderate levels in the heterozygous mutants, and very low levels of binding of GABPA 
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in the wildtype TERT cell line (107). The allele-specific methylation of TERT also 
affected the MYC binding site at the minimal promoter, which exhibits lower levels of 
methylation on the mutant allele. As with GABPA, we found MYC binding to the TERT 
mutant allele in an allele-specific manner.  
 
Ours is the first study to show allele-specific binding of MYC. MYC is a known direct 
activator of TERT transcription (110). Our previous work showed enrichment for MYC at 
the TERT promoter in the thyroid cancer cell lines (107). As MYC has been shown to be 
methylation-sensitive in binding to its consensus site at other gene locations (95), the 
higher level of methylation at the TERT binding site on the wildtype allele may partially 
prohibit MYC binding, therefore lessening activation. Our results contradict a previous 
study in cancer cell lines (27) that concluded MYC was a mutation-independent 
activating factor of TERT. The previous study examined the effects on TERT expression 
after MYC knockdown in cancer cell lines, and therefore could be the result of MYC’s 
role at other loci. Conversely, our study specifically interrogated MYC binding to the 
TERT promoter, where we did observe mutation-dependent MYC binding.  
 
In addition to the allele-specific binding of activators MYC and GABPA and the 
activating chromatin mark H3K4me3, we confirmed monoallelic transcription of TERT in 
the heterozygous TERT mutant thyroid cancer cell lines by utilizing SNPs identified in 
the coding sequence. Analysis of TPC-1 showed that the TERT mutation and the SNP on 
the expressed transcript occur on the same allele, providing the first direct evidence of 
TERT expression solely from the mutant TERT allele. Furthermore, this monoallelic 
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expression resulted from monoallelic transcriptional activation of TERT in the thyroid 
cancer cell lines. As expected, we observed the lowest levels of TERT transcription and 
telomerase activity in the TERT wildtype cancer cell line, WRO, and the normal thyroid 
cell line, Nthy-ori-3. It is important to note that while Nthy-ori-3 is utilized as a normal 
thyroid cell line, the cell line is immortalized with multiple mutations and chromosomal 
abnormalities, although none are known to be oncogenic (116). The three heterozygous 
TERT mutant thyroid cancer cell lines showed the highest levels of TERT expression and 
telomerase activity. Surprisingly, the TERT homozygous mutant cell line, FTC-133, 
showed less TERT transcript and telomerase activity than the heterozygous cell lines. 
Previous study of another TERT homozygous mutant cell line, SW1736, also showed less 
TERT expression in the cell line than in heterozygous mutant cell lines (29). This may 
suggest additional post-transcriptional and post-translational regulatory processes 
affecting telomerase activity.  
 
In summary, we have demonstrated and characterized allele-specific methylation at the 
TERT promoter and into the gene body in heterozygous TERT mutant thyroid cancer cell 
lines. Furthermore, lower levels of methylation at the GABPA and MYC binding site on 
the TERT mutant allele correlated with allele-specific binding of these two transcriptional 
activators. The chromatin mark H3K4me3 further confirmed activation of only the 
mutant allele, while the H3K27me3 mark also confirmed silencing of the wildtype allele. 
These regulatory mechanisms result in monoallelic transcription of TERT in heterozygous 
mutant cell lines, corroborated by unique SNPs that showed TERT transcription 
originating solely from the mutant TERT allele.  
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Figure 11: DNA methylation assessed by nanopore Cas9 targeted sequencing 
(nCATS) shows drop in methylation surrounding TSS and higher levels of 






A) Read-level methylation plots using IGV. Depth of coverage at the TERT gene is 
shown in the top graph where the coverage at each base is indicated by the grey line plot 
with the minimum and maximum CpG coverage stated. Each horizontal line in the 
wildtype (top) and mutant allele (bottom) plots is a single nCATS read. Red denotes a 
methylated CpG and blue denotes an unmethylated CpG. The TERT chromosomal 
coordinates are shown at the bottom to designate position. B) Average methylation plots. 
The wildtype allele is depicted in purple and the mutant TERT allele in orange. Individual 
dots represent methylation at an individual CpG site. The orange or purple line represents 
the smoothened level of methylation over the entire area. The black arrow denotes the 
transcription start site (TSS). TERT exons 1 and 2 are shown by thick black lines. The 
gene reads from right to left into the gene body, denoted by the dashed arrow. The red 




















Figure 12: Average methylation plots of the TERT promoter and gene body in 
homozygous vs heterozygous TERT mutant thyroid cancer cell lines 
 
Methylation levels were in the following thyroid cancer cell lines: wildtype cell line 
WRO, heterozygous TERT mutant cell lines BCPAP and FTC-238, and homozygous 
mutant cell line FTC-133. The wildtype allele is depicted in purple and the mutant TERT 
allele in orange. Individual dots represent methylation at an individual CpG site. The 
purple or orange line represents the smoothened methylation over the entire area, 
showing drops in methylation surrounding the TSS, and higher levels in the gene body, of 
the mutant allele. The black arrow denotes the transcription start site (TSS). TERT exons 
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1 and 2 are shown by thick black lines. The gene reads from right to left into the gene 

























Figure 13: Allele-specific methylation at the TERT promoter in thyroid cancer cell 
lines by nCATS 
 
Methylation levels at the TERT minimal promoter, including the TSS, GABPA binding site 
(TERT mutation), and MYC binding site in heterozygous TERT mutant cell lines TPC-1, 
BCPAP, and FTC-238, wildtype cell line WRO, and homozygous TERT mutant cell line 
FTC-133. CpG location is denoted by chromosomal location. The wildtype allele is shown 

























Figure 14: Allele-specific methylation at the TERT promoter in thyroid cancer cell 
lines by nCATS 
 
Allele-specific transcription factor binding of MYC and GABPA at the TERT promoter in 
heterozygous TERT mutant thyroid cancer cell lines. Chromatin immunoprecipitation 
(ChIP) in the heterozygous TERT mutant thyroid cancer cell lines with either MYC or 
GABPA antibodies followed by Sanger sequencing of the TERT promoter at the -124 
C>T TERT mutation, compared to input genomic DNA before ChIP. At the -124 TERT 
position, the mutant allele is represented by the red curve (T), while the wildtype allele is 
represented by the blue curve (C). The input genomic DNA shows the presence of both 
alleles at the -124 position, while the immunoprecipitated DNA shows only the red curve 






Figure 15: Allele-specific chromatin marks at the TERT minimal promoter in 
thyroid cancer cell lines 
 
A) ChIP with either H3K4me3 (activating chromatin mark) or H3K27me3 (silencing 
chromatin mark) antibodies. Binding was measured relative to 5% input chromatin, and 
binding at the TERT locus assessed by qPCR. H3K4me3 binding at the TERT promoter 
was most abundant in the homozygous mutant cell line FTC-133 (black bar), 
intermediate in the heterozygous mutant cell lines (grey bars), and least abundant in the 
homozygous wildtype cell lines (white bars with cancer cell line WRO denoted by stipple 
compared to normal cell line NThy-ori-3). H3K27me3 binding was reciprocal of the 
H3K4me3 binding. All error bars represent standard error within triplicates. B) Sanger 
sequencing of the TERT promoter immunoprecipitated DNA of heterozygous TERT 
mutant thyroid cancer cell lines at the -124 C>T mutation, compared to input genomic 
DNA before ChIP. At the -124 TERT position, the mutant allele is represented by the red 
curve (T), while the wildtype allele is represented by the blue curve (C). The input 
genomic DNA shows the presence of both alleles at the -124 position, while the 
H3K4me3 immunoprecipitated DNA shows only the red curve indicative of the mutant 








Figure 16: TERT monoallelic expression in heterozygous TERT mutant thyroid 
cancer cell lines 
 
Sanger sequencing analysis of the exon 2 region and 3’UTR region of TERT surrounding 
SNPs rs2736098 and rs2853690 respectively in amplified genomic DNA, as well as 
cDNA, from TERT heterozygous mutant cell lines TPC-1, BCPAP, and FTC-238. While 
the genomic DNA in all cell lines showed both alleles of the SNP, the cDNA showed 











Figure 17: Heterozygous TERT mutant thyroid cancer cell lines exhibit higher levels 
of TERT transcript and telomerase activity compared to homozygous wildtype or 
mutant thyroid cancer cell lines 
 
A) TERT transcript level measured by qRT-PCR in thyroid cancer cell lines, and B) 
relative telomerase activity (RTA) in thyroid cancer cell lines compared to HEK293T 
cells. White denotes homozygous wildtype (stippling denotes the TERT homozygous 
wildtype cancer cell line from the normal thyroid cell line), grey denotes heterozygous 
mutant, and black denotes homozygous mutant thyroid cancer cell lines. Standard 





Figure S6: H3K4me3 and H3K27me3 ChIP-qPCR at control loci 
 
Binding was measured relative to 5% input chromatin in the indicated cell lines by ChIP-
qPCR for A) H3K4me3. The Actin locus was used as a positive control, and MYT1 as a 
negative control for H3K4me3 binding, B) H3K27me3. The MYT1 locus was used as a 
positive control, and Actin as a negative control. Both chromatin marks showed robust 
binding as expected in the positive controls, and low binding in the negative controls. All 
















Figure S7: Methylation calls for Illumina bisulfite sequencing and nCATS are 
similar 
 
Illumina bisulfite sequencing (gray) at the TERT promoter region compared to nCATS 
(black) in the same region in thyroid cancer cell lines A) TPC-1 B) BCPAP C) FTC-133 


















Figure S8: Thyroid cancer cell lines show TSS methylation level correlated with 
TERT promoter mutation status 
 
Read-level methylation plots using IGV for heterozygous TERT mutant thyroid cancer 
cell lines A) BCPAP and B) FTC-238, homozygous mutant C) FTC-133, and 
homozygous wildtype D) WRO at the promoter and gene body for TERT. Depth of 
coverage at the TERT gene is shown in the top graph where the coverage at each base is 
shown by the grey line plot with the minimum and maximum CpG coverage stated. Each 
horizontal line in the mutant and wildtype allele depiction is a single nCATS read sorted 
based on the TERT promoter mutation as mutant or wildtype, where red denotes a 
methylated CpG and blue denotes an unmethylated CpG. The TERT chromosomal 











Figure S9: GABPA binds more abundantly than ETV5 at the TERT promoter in all 
thyroid cancer cell lines 
 
Binding was measured relative to 5% input chromatin in the indicated cell lines by ChIP-

















Chapter 4: CRISPR/Cas9 editing the TERT promoter 
Introduction 
Recently, we showed allele-specific methylation, chromatin marks, transcription factor 
binding, and expression in thyroid cancer cell lines harboring the TERT mutation (117). 
Briefly, the mutant allele showed hypomethylation surrounding the transcription start site 
(TSS), with the active chromatin mark H3K4me3, and bound transcriptional activators 
GABPA and MYC. The wildtype allele showed hypermethylation at the TSS, the silencing 
mark H3K27me3, and no bound transcriptional activators. Further, transcription was 
mono-allelic, from the mutant allele (117). This allele-specific pattern of methylation, 
chromatin marks, and transcription factor binding has been demonstrated in other cancer 
cell types as well (26, 52, 118). Nevertheless, the evidence linking the TERT mutation with 
TERT promoter status still remains correlative and not causative. Concluding my thesis, 
we are further advancing this work by exploring the causative role of the mutation and its 
acute effects on promoter DNA methylation, chromatin marks, and expression. 
 
In our current study, we conducted CRISPR/Cas9 editing of the TERT promoter in the 
heterozygous TERT mutant thyroid cancer cell line, TPC-1, to create the full set of possible 
TERT promoter mutation states, in an isogenic background. TPC-1 is a near-diploid PTC 
derived cell line that carries a RET/PTC1 rearrangement. Through use of the CRISPR/Cas9 
editing system, we are creating a controlled study system in a thyroid cancer cell line to 
study the causative role of the TERT promoter mutations on TERT transcriptional 
regulation and telomerase activity, furthering our previous investigations. We will 
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interrogate the effect of changing the TERT promoter mutation status on TERT promoter 
methylation, histone modifications, transcriptional activator binding, and TERT 
expression. This work will further our understanding of the mechanisms of activating TERT 
promoter mutations and their role in telomerase regulation in cancer.  
 
Results 
Two-step CRISPR/Cas9 editing of the TERT promoter  
 
Given the highly GC-rich status of the TERT promoter, the low complexity base 
composition leads to many potential off-target sites when designing single guide RNAs 
(sgRNAs) to target TERT (19, 119). Previous attempts to target TERT with one sgRNA 
have resulted in great cell toxicity and inefficient editing (19, 119). Therefore, Xi et al. 
devised a two-step CRISPR/Cas9 editing method to modify the TERT promoter near the 
TERT mutation, which we adapted to edit our thyroid cancer cell line. Briefly, as shown 
in Figure 18, the first step involves a single sgRNA targeted to the TERT promoter, where 
Cas9 cuts at -147/148, relative to the translational start site. The homology directed repair 
(HDR) template also transfected into the cell contains a GFP expression cassette, which 
is inserted at TERT between -139/140 to disrupt the sgRNA recognition site (Figure 18B). 
In the second editing step, two sgRNAs are used to target and excise the inserted GFP 
cassette, and an HDR template is provided to repair to the endogenous TERT sequence, 
except that the repair templates contain wildtype or mutant (-124) TERT promoter (Figure 




Editing of TPC-1 cell line  
We utilized this system in the TERT heterozygous mutant PTC cell line, TPC-1, to create 
cell lines with isogenic backgrounds but differing TERT mutation states. This cell line 
was selected from our repertoire of cell lines as it was diploid at the chromosome 5p15 
locus where TERT is located, which we determined by fluorescence in situ hybridization 
(FISH) (Supplemental Figure 10). In addition to the HDR template containing wild type 
or mutant TERT sequences, we introduced a SNP in exon 1 in order to track allele-
specific transcription and methylation of the edited allele. We identified a SNP occurring 
at low frequency in the Trans-Omics for Precision Medicine (TOPMED) whole genome 
sequencing project, SNP rs750133706. We performed site directed mutagenesis of the 
HDR templates to include the SNP, which does not occur in the TPC-1 cell line, in the 
introduced template (Supplemental Figure 11).  
 
After screening over 200 single cell-derived clones, we obtained two of the necessary 
three cell lines with the edited TERT promoter and new SNP in exon 1 (Figure 19). We 
have ongoing work to finish the CRISPR/Cas9 editing to complete our repertoire of 
isogenic background cell lines with the following mutation states: The parental TPC-1 
heterozygous mutant cell line, a homozygous mutant cell line, and a wildtype TERT cell 
line. The necessary control cell lines are also being constructed, such that we can control 
for the impact of editing the cells on TERT regulation (editing the TERT promoter and 





Characterizing TERT regulation in edited cell lines  
With these engineered cell lines, we will be able to further characterize TERT promoter 
regulation (Figure 20) as a direct consequence of genetic changes we have introduced. 
Briefly, we will conduct nCATS methylation analysis of the TERT promoter in our edited 
cell lines, and utilizing the TERT mutation and exon 1 SNP, be able to determine allele-
specific methylation of the TERT promoter. This will allow us to determine if altering the 
TERT mutation state affects the TERT methylation pattern. We will next conduct ChIP-
qPCR, as previously done, to characterize transcriptional activators GABPA and MYC 
binding at the TERT promoter in the edited cell lines. Additionally, ChIP-qPCR for the 
chromatin marks H3K4me3 and H3K27me3 will be conducted to determine the 
chromatin state of the edited alleles. Lastly, we will characterize TERT expression in the 
edited cell lines, and again utilizing the exon 1 SNP as allele-specific marker, we will 
determine the allele-specific expression patterns of the cells.  
 
Discussion 
While previous studies have characterized TERT promoter regulation in different cancer 
subtypes with the TERT mutation, no study has definitively established a causative 
relationship between the TERT promoter mutation and changes in TERT promoter 
methylation, transcriptional activator binding, histone marks, and expression. The end of 
my thesis work has been devoted to developing CRISPR/Cas9 edited cell lines as a tool 
to answer this question regarding TERT regulation. Previous correlative studies were 
conducted in differing cell lines with different mutational backgrounds. Here, we use one 
cell line, TPC-1, to establish multiple isogenic cell lines that have the same mutational 
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background except for the TERT promoter, providing an excellent system to study the 
acute effects of the TERT promoter mutation on TERT regulation. Further, by introducing 
a synonymous SNP into the first exon, the cell lines will have more utility for the study of 
allelic expression, and in cell lines homozygous at the TERT promoter, the SNP provides 
a way to track the edited allele to still provide allele-specific context. 
 
We would expect, if the correlation from previous studies holds true, that a wildtype 
TERT allele edited to be a mutant allele would result in a decrease in promoter 
methylation, increased MYC and GABPA binding, increased H3K4me3 at the TERT 
promoter, and increased expression of the allele. Alternatively, a mutant TERT allele 
edited to remove the mutation would be expected to result in increased promoter 
methylation, decreased factor binding, increased H3K27me3, and decreased expression. 
However, one competing scenario would be the artificially introduced mutation would 
not have immediate epigenetic and/or transcriptional consequences, which would require 
exploring alternative hypotheses. All of the experiments detailed in Figure 20 have been 
previously conducted and are described in established protocols which can be completed 
with minimal optimization by members of the Umbricht lab after completion of my time 
in lab. Therefore, with the tools created, we will be able to finally answer the question 
concerning TERT promoter mutations causative role in effecting TERT promoter 






Figure 18: CRISPR-Cas9 editing of the TERT promoter  
 
A) Diagram of editing the TERT mutation status in a parental, heterozygous mutant cell 
line. The wildtype (WT) allele is white, the mutant (Mut) is black. In Step 1, the eGFP 
cassette (green) may insert into either allele. In Step 2, dependent on the repair template 
(RT) containing the WT or Mut allele, different TERT promoter mutation states result. B) 
Schematic of the protocol to edit the TERT promoter. In Step 1, a double-stranded break 
is generated at -147/148 by Cas9 (scissors). A repair template is transfected into cells 
containing the SV-40 driven eGFP expression cassette surrounded by homology arms to 
the TERT promoter. After selection of cells that contain the modified promoter, in Step 2 
the eGFP cassette is removed by two introduced double stranded breaks surrounding the 
cassette. Different repair templates are provided that include the endogenous TERT 
promoter sequence with WT or Mut TERT (depicted by an X) as well as the rs750133706 














Figure 19: Sanger sequencing of the TERT promoter in edited cells 
 
Sanger sequencing analysis of the TERT promoter at the -124C>T mutation and the exon 
1 region surrounding SNP rs750133706 in amplified genomic DNA from the parental 
TPC-1 cell line, and the CRISPR/Cas9 edited cell lines. The columns depict each cell line 
and the cell line’s TERT mutation status. The base pair of interest is shown in by the 

















Figure 20: Flow chart for characterization of edited cell lines 
 
Schematic of characterization elements in gray to be completed with the edited TERT 
promoter cell lines, including methylation, transcription factor binding, histone marks, 





























Figure S10: Chromosome 5 FISH of thyroid cancer cell lines  
 
 
Fluorescence in situ hybridization (FISH) of two representative thyroid cancer cell lines, 
TPC-1 and FTC-133. FISH analysis was performed with a dual color probe for 
chromosome 5 that detects a locus on the short arm, 5p15.2 (green signal), and the EGR1 
gene on the long arm, 5q31 (orange signal). Counts per cell are shown as the signal 
number for the orange probe (O) followed by the signal number for the green probe (G), 













Figure S11: Sanger sequencing of TERT exon 1 SNP  
 
 
Sanger sequencing analysis of the exon 1 region of TERT surrounding SNP rs750133706 
in amplified genomic DNA from the cell line TPC-1 and CRISPR-Cas9 edited TPC-1. 
While the parental DNA showed one allele of the SNP, the edited line showed both 











Chapter 5: Conclusions and Future Directions 
In Figure 1, the reader was provided with an overview of the previously known 
mechanisms of TERT regulation in cancer cells. Understanding how these mechanisms 
activate telomerase, as well as the interplay between the regulatory mechanisms, will 
allow us to further unravel the ways in which cancer cells manipulate normal cellular 
machinery and regulation during carcinogenesis. The experiments I have conducted 
during my PhD have contributed to the body of knowledge surrounding TERT regulation 
in cancer cells. While previous studies in other cancer subtypes have established a pattern 
of TERT promoter methylation, transcription factor binding, and chromatin landscape, 
previous studies have not explored the pattern of TERT regulation in thyroid cancer. As 
thyroid cancer has one of the least perturbed cancer genomes, with few copy number 
variations and low mutation density (22), it is an ideal system in which to study 
telomerase activation.  
 
My experiments, the first comprehensive study of TERT promoter methylation in thyroid 
cancer, demonstrated a pattern consistent with other cancer subtypes, in which the 
minimal promoter surrounding the TSS is hypomethylated, and the upstream promoter is 
hypermethylated. Moreover, close investigation of bisulfite sequencing data revealed a 
pattern consistent with allele-specific methylation. When we followed this path utilizing a 
novel sequencing technology, nCATS, that did not obscure the TERT promoter mutations 
as bisulfite-based approaches had, we were able to confirm allele-specific methylation in 
thyroid cancer cells heterozygous for the TERT mutation, in which the mutant allele was 
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significantly less methylated surrounding the TSS than the wildtype allele, mirroring the 
pattern of an actively transcribed gene. Further, transcriptional activators GABPA and 
MYC were found to bind only to the mutant allele, with active chromatin mark 
H3K4me3 associated with the mutant allele and the silencing mark H3K27me3 
associated with the wildtype allele. Finally, we were able to prove monoallelic expression 
of the mutant TERT allele for the first time. These data suggest the TERT promoter 
mutation may alter the TERT promoter landscape in mutant cells, causing a selection to 
an activated allele state and active telomerase. This work sheds light on the never before 
characterized TERT regulation in thyroid cancer, and is applicable more broadly in 
understanding TERT regulation in cancer.  
 
The work described here also raises a number of questions regarding the cause and effect 
relationship between the TERT promoter mutations and TERT regulation. Previous 
studies, including ours, have shown a correlation between the TERT promoter mutations 
and less promoter DNA methylation, active chromatin marks, increased activator 
binding, and higher TERT transcription (52, 56, 117). One clear goal, as stated in Chapter 
4, is to explore the causative effect of the TERT promoter mutation on the other TERT 
regulatory mechanisms. This will help to further delineate the path of immortalization for 
cancer cells, by understanding what role the TERT mutation plays in cancer. As over 90% 
of immortalized thyroid cancer cell lines harbor the TERT mutation (11), there seems to 
be a clear selection for the mutation to confer a proliferative advantage. However, while 
understanding the role of the TERT mutations will progress our understanding of TERT 
regulation, unlike the immortalized cell lines, the majority of cancers do not harbor the 
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TERT mutation (141), yet approximately 90% (5) display active telomerase. This is 
indicative of additional mechanisms that activate telomerase, independent of the TERT 
mutation, that are active in the earliest stages of carcinogenesis. Further work is needed to 
determine how telomerase is activated without the TERT mutation, which could be driven 
by changes in TERT promoter methylation or factor binding.  
 
To better understand dysregulation in cancer, it is imperative to understand regulation in 
normal somatic cells. Indeed, there is a dearth of information surrounding TERT 
regulation in normal tissue, partly due to problems surrounding its study in non-
transformed cells. Most of the work in TERT regulation has been conducted in 
immortalized cell lines, in which the process of immortalization of cell lines may involve 
activation of TERT, thereby confounding its interpretation. Studies in untransformed cells 
are more challenging, as these cells do not grow in cell culture for a sufficient period of 
time to be able to complete experiments. However, understanding TERT regulation in 
these normal cells is crucial. Normal tissue that does not express telomerase appears to be 
hypomethylated throughout the TERT promoter, including at the minimal promoter which 
is also hypomethylated in cancer. This raises the question of the role of the 
hypomethylated region in cancer, and whether it is necessary but not sufficient to activate 
TERT, as well as how TERT is inactivated in normal tissue. These questions should be 
explored through additional studies involving normal tissue as well as short term cell 




Lastly, as briefly described above, the role of the TERT dual methylation pattern in 
cancer cells remains to be completely understood, specifically as to what promoter 
methylation pattern is both necessary and sufficient for TERT transcriptional activation. 
We have found the upstream TERT promoter to be hypermethylated in thyroid cancer cell 
lines, following the same pattern as other cancer types, compared to normal tissue. 
Further, the methylation of one CpG, cg11625005, in the upstream promoter in 
glioblastoma is utilized as a prognostic biomarker, where hypermethylation correlates 
with poor prognosis (10). The role of the hypermethylation in cancer, however, is still 
poorly understood. Our identification of foci of hypomethylation within the 
hypermethylated upstream promoter, and further work identifying putative binding sites 
for activators MYC and GSC at these foci (107), hints at another level of regulation 
which may be occurring. Recently, an in-depth TERT methylation analysis of 833 cancer 
cell lines also identified foci of lower methylation in the upstream hypermethylated 
region (142), and warrant further investigation of their role in TERT regulation. 
Experiments such as targeted DNA demethylation by CRISPR/dCas9-mediated 
epigenome editing at the hypermethylated upstream TERT promoter may help elucidate 
the role of this region on TERT regulation.  
 
Overall, understanding TERT regulation in thyroid cancer will lead to a better 
comprehension of the overall mechanism of telomerase activation and immortalization of 
cancer cells. We recognize that TERT regulation is not simple, but rather multifaceted, 
comprising activating point mutations, DNA methylation changes, altered transcription 
factor binding, chromatin accessibility alterations, and alternative splicing. These 
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complex regulatory strategies highlight the importance for somatic cells to keep TERT 
transcriptionally silenced, with multiple regulatory elements to sustain the silencing. 
While our work has provided a clearer picture of TERT regulation in thyroid cancer cells, 
there is still much work to be done, including establishing a causative role of the TERT 
promoter mutations on regulation, a clearer understanding of TERT regulation in normal 
stem cells and somatic cells, and further exploration into the regulatory role of the dual 


















Materials and Methods 
Cell Lines and Culture Conditions: Five differentiated thyroid cancer cell lines (PTC 
lines TPC-1(120) and BCPAP (121) or FTC lines FTC-133, FTC-238, and WRO) were 
kindly provided by Dr. Motoyasu Saji (The Ohio State University Wexner Medical Center, 
Columbus, OH). The SV40-transformed normal thyroid follicular epithelial cell line Nthy-
ori-3 (122) was kindly provided by Dr. Thomas Fahey (Weill Cornell Medical Center, New 
York, NY). All cell lines were authenticated using short tandem repeat profiling. The cell 
lines BCPAP and Nthy-ori-3 were grown in Roswell Park Memorial Institute-1640 (RPMI-
1640; Sigma-Aldrich, St. Louis, MO) medium with 10% heat-inactivated fetal bovine 
serum (FBS) (GE Healthcare Life Sciences, Marlborough, MA), while TPC1, FTC133, 
FTC 236, FTC238, and WRO were grown in HyClone Dulbecco’s Modified Eagle 
Medium (DMEM) (GE Healthcare Life Sciences) with 10% FBS. All cultures were 
supplemented with 1x antibiotic antimycotic solution (Sigma-Aldrich), 2 mM L-glutamine 
(Life Technologies, Carlsbad, CA), and 1x MEM-Non-Essential Amino Acids (Quality 
Biological, Gaithersburg, MD) and grown exponentially at 37°C and 5% CO2. 
 
Patient Samples: Six frozen benign thyroid tissue samples were selected from our 
thyroid tissue bank, which has been approved by Institutional Review Board at Johns 
Hopkins Medical Institutions. Samples were immediately placed on ice, prosected and 
reviewed in the Department of Pathology, snap frozen in liquid nitrogen, and stored at -
80˚C until use. Five µm Cryostat H&E sections were obtained to locate tumor-adjacent 




DNA Isolation: Genomic DNA from cell lines and patient tissue was isolated utilizing 
by Proteinase K digestion, phenol/chloroform extraction, and ethanol precipitation, as 
described previously (123). DNA was diluted in 1x Low-EDTA TE pH8 (Quality 
Biological). 
 
Sanger Sequencing: Sanger sequencing was performed to confirm the mutation status of 
the cell lines for TERT and BRAF. The target regions surrounding the TERT promoter 
mutation (-124 C>T) and the BRAFV600E mutation were amplified by PCR using 
primers listed in Supplemental Table 3, followed by Sanger sequencing using the 
sequencing primers (11, 92).  
 
Bisulfite Modification and PCR of TERT Promoter: Isolated DNA (100 ng) was used 
for bisulfite treatment using the EZ DNA Methylation-Lightning Kit, according to 
manufacturer’s guidelines (Zymo Research, Irvine, CA), and eluted in 11 µl H2O. 
Bisulfite modified DNA was amplified with three separate tiled primer sets listed in 
Supplemental Table 3, amplifying the region -662 to +174 relative to the TERT TSS. The 
50 µl PCR amplification reaction contained 5 µl of bisulfite treated DNA (approximately 
half of the 100 ng bisulfite-treated input DNA), 300 nM of forward and reverse tile 
primers, and 25 µl KAPA HiFi HotStart Uracil+ ReadyMix (2X) (KAPA Biosystems, 
Wilmington, MA) using the ProFlex PCR System (Applied Biosystems, Foster City, CA) 
[2 minutes 95°C, 35 cycles x (20 seconds 98°C, 20 seconds (T1 58°C/T2 54°C/T3 54°C, 




Bisulfite Library Preparation and Sequencing: PCR products from the bisulfite treated 
TERT tiles were purified with Agencourt AMPure XP beads, using 1.8x beads (Beckman 
Coulter Life Sciences, Indianapolis, IN) and quantified using the Qubit dsDNA HS Assay 
Kit (ThermoFisher Scientific, Waltham, MA). The NEBNext Ultra DNA Library Prep 
Kit for Illumina (New England Biolabs, Ipswich, MA) protocol was followed for library 
preparation with no size-selection, with DNA input of 20, 40, 200 ng of pooled 3 
promoter tiles, T1, T2, T3 respectively. Differences in input was due to differences in the 
tiles’ on-target amplicon amounts, with the tile displaying the least on-target amplicon 
being the tile with the highest input. Library concentration and size distribution was 
quantified with the High Sensitivity DNA kit on the 2100 Bioanalyzer (Agilent, Santa 
Clara, CA) and KAPA Library Quantification Kit for Illumina Platforms (KAPA). A 12 
pM sample library for promoter bisulfite sequencing with 30% PhiX control was paired-
end sequenced on the MiSeq v3 600 PE system (Illumina, San Diego, CA) for a targeted 
minimum of 10,000 reads per amplicon. 
 
Data Processing for Bisulfite Sequencing: TERT promoter methylation status was 
analyzed with the Bismark (124) software package. Bisulfite conversion and mapping to 
the Human Genome Reference Consortium build 37 (GRCh37) was performed on 
trimmed reads (Trim Galore) with a quality Phred score cutoff of 30 (125). Sequencing 
coverage for each CpG was analyzed with bsseq (126). A CpG site was included in 
analysis if the sequencing coverage was over 60 and present in more than two cell lines. 
Epiallele analysis at the MYC binding site and chr5:1,295,587-1,295,800 was conducted 
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through MethPat (91), using the settings --amplicons, --filterpartial, --min_cpg_percent 1. 
Analysis of differentially methylated regions was conducted through software package 
bsseq (126), with the settings ns=5, h=15. Differentially methylated regions were 
determined with a quantile-based cutoff, c(0.1,0.9). The Integrative Genomics Viewer 
(IGV) (127) was utilized to visualize differentially methylated regions.  
 
Chromatin Immunoprecipitation (ChIP) Analysis: DTC cells were grown to 85% 
confluency in 15 cm plates. ChIP was performed as described previously for cell lines 
(128). For ChIP analysis in normal thyroid tissue, the Novus Biologicals protocol (129) 
was followed. Cells were fixed for 8 minutes in 1% formaldehyde. Chromatin was 
sheared by sonication for 2x [4x 20s on/20s off] by the Bioruptor Pico (Diagenode, 
Denville, NJ). The following antibodies were used (10 µg per ChIP): anti-CTCF (#2899, 
Cell Signaling Technology, Danvers, CA), anti-MYC (#9402, Cell Signaling 
Technology), anti-GABPA (#27795, ThermoFisher), anti-GSC (#40495, ThermoFisher), 
anti-H3K4me3 (#9727, Cell Signaling Technology), anti-H3K27me3 (#9733, Cell 
Signaling Technology), and anti-ETV5 (#30023, ThermoFisher). DNA was purified by 
MinElute PCR Purification Kit (Qiagen, Hilden, Germany). ChIP and input DNA were 
analyzed by qPCR with Sybr Green and melt curve analysis, with the primer sets listed in 
Supplemental Table 4. Three replicate PCR reactions were carried out for each sample 
with two biological replicates, with positive and negative control regions for each 
antibody. Factor binding was determined by the percent of input normalization method 
(133), normalizing the binding at the TERT locus, encompassing the TERT promoter 
mutation and TSS, relative to DNA input into ChIP. After ChIP, immunoprecipitated 
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DNA and input DNA was amplified by PCR surrounding the TERT -124 C>T mutation 
and Sanger sequenced (107).  
 
qRT-PCR for TERT Expression: RNA from the DTC cell lines was extracted by Trizol 
isolation, as described previously (131). RNA from normal thyroid tissue was extracted 
using the Highpure FFPE RNA kit (Roche, Basel, Switzerland) following the 
manufacturer’s protocol. RNA was reverse transcribed to cDNA using SuperScript III 
Reverse Transcriptase (ThermoFisher) according to manufacturer instructions. 
Quantitative PCR was performed as previously described with SYBR Green PCR Master 
Mix (ThermoFisher), with primers designed to detect the full-length TERT transcript 
levels (70). The expression level of TERT was normalized to GAPDH. 
 
Nanopore Cas9 Targeted-Sequencing (nCATS) of TERT: nCATS was conducted as 
previously described (111). Briefly, forward and reverse CRISPR RNAs (crRNAs) were 
designed to target 7.806 kb surrounding the TERT region at chr5:1,288,699-1,296,505: F 
‘AAGGCTTAGGGATCACTAAG’, and R ’AGCGGCAGGTGCCCAGAATA’. crRNAs 
were mixed in equimolar amounts to a final concentration of 100 µM. After duplex 
formation, dephosphorylation of the genomic DNA, cleavage and dA tailing, adaptor 
ligation, and clean-up (111), each sample was sequenced on a nanopore flow cell (version 
9.4.1) using the GridION sequencer (Oxford Nanopore Technologies, Oxford, UK).  
 
Data Processing for nCATS Methylation: Analysis of the nanopore data was 
conducted as previously described (111). Base calling to generate FASTQ reads was 
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performed by the GUPPY algorithm. The resulting reads were aligned to the human 
genome, hg19, by Minimap2 (132). CpG methylation calling was conducted using 
nanopolish (133). Reads were phased into wildtype or mutant allele by identifying the 
promoter motif in fastq reads. 
 
Real-time Quantitative Telomeric Repeat Amplification Protocol (q-TRAP): Cells 
were lysed in CHAPS lysis buffer (Cell Signaling Technology), and incubated on ice for 
20 minutes. Cell debris was removed by centrifugation, and total protein concentration 
measured. Heat inactivation, no template, and telomerase quantitation controls were 
performed using serial dilutions of HEK293T cells (ATCC ACS-4500). The 25 µl 
reaction contained 1x Sybr Green (ThermoFisher), 0.1 µg of TS and ASX primers, and 
250 ng of protein extract. Quantitative PCR was performed as previously described (134).  
 
Allele-Specific Transcription Characterization: SNPs in the thyroid cancer cell lines 
were identified by Sanger sequencing of genomic DNA in the TERT 3’ untranslated 
region (UTR), and by IGV examination of the nCATS data in the TERT 5’ UTR and 
exons 1 and 2. Isolated RNA from the cell lines was DNase I treated and reverse 
transcribed as above, then amplified at the SNP location (Supplemental Table 5) and 
Sanger sequenced utilizing the forward primer to determine genotype.  
 
Plasmid Construction and Transfection: The pX330 plasmid vector containing Cas9 
and the sgRNAs (sgRNA sequences in Supplemental Table 6), as described in (135), 
were kindly provided by Dr. Thomas R. Cech (The University of Colorado Boulder, 
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Boulder, CO). The repair template with the eGFP expression cassette or the endogenous 
TERT sequence from -589 to +353 in the pUC57-Kan plasmid were also kindly provided 
by Dr. Thomas R. Cech. Site-directed mutagenesis was performed on the repair template 
plasmid containing the TERT sequence to add the TERT promoter mutation (-124C>T) as 
well as two exon 1 SNPs (rs750133706 and rs1459602769) in different combinations. 
Briefly, point mutations were introduced by PCR, using the Q5 Site-Directed 
Mutagenesis Kit (New England Biolabs), according to the manufacturer’s protocol. PCRs 
were run for 25 cycles of 2 min 15 s at 72°C. The resulting mutant plasmids were verified 
by Sanger sequencing. One million cells were transfected with 1.0 ug pX330 Cas9-gRNA 
plasmid and 1.0 ug pUC67-Kan repair template plasmid using Lipofectamine 2000 
Reagent (ThermoFisher, Waltham, MA) according to the manufacturer’s instructions.  
 
Fluorescence Activated Cell Sorting (FACS): Cells were trypsinized and re-suspended 
to a single cell suspension with cell strainer caps (BD Biosciences, San Jose, CA) in sorting 
buffer (1x PBS, 1% heat-inactivated FBS, Penicillin-Streptomycin, 2 mM EDTA). Cells 
were sorted by GFP signal with a 100 uM nozzle on the FACSAria IIu Cell Sorter (BD 
Biosciences). Cells were collected and single cell seeded into 96 well plates. 
 
Post-CRISPR Editing DNA Extraction and Analysis: DNA was extracted from each 
well by Extract-N-Amp Blood PCR Kit (Millipore Sigma, Burlington, MA) according to 
the manufacturer’s instructions. Extracted DNA was then PCR amplified surrounding the 
TERT edited locus (primers in Supplemental Table 7) and Sanger sequenced to confirm the 




Table S3: Primers for bisulfite and Sanger sequencing analysis 




TERT -124 C>T 
Sanger amplicon 
162 F 5’ GTCCTGCCCCTTCACCTTC 3’ 
R 5’ AGCGCTGCCTGAAACTCG 3’ 
TERT -124 C>T 
Sanger sequencing 
N/A 5’ TTCACCTTCCAGCTCCGC 3’ 
BRAFV600E 
Sanger amplicon 
180 F 5’ AACTCTTCATAATGCTTGCTCTGA 3’ 




N/A 5’ AATAGGTGATTTTGGTCTAGCTACAG 3’ 
BSa tile 1 
(-662 to -395)b  
267 F 5’ GGGTTTGTGTTAAGGAGTTTAAGT 3’ 
R 5’ CATAATATAAAAACCCTAAAAACAAAT 
3’ 
BS tile 2 
(-420 to -126) 
296 F 5’ TTGTTTTTAGGGTTTTTATATTATGGT 3’ 
R 5’ AAACTAAAAAATAAAAAAACAAAAC 3’ 
BS tile 3 
(-159 to +174) 
333 F 5’ GGTATTYGTTTTGTTTTTTTATTTTT 3’ 
R 5’ CACCAACCRCCAACCCTAAA 3’  
















Table S4: Primers for ChIP-qPCR analysis 
Primer Name Product Size (bp) Sequences (5’-> 3’) 
CTCF   








TERT 171 F CTGCTGCGCACGTGGGAAGCC 
R GTCCCCGCGCTGCACCAGCC 
MYC   












TERT 2 80 F TTCACGTCCGGCATTCG 
R CCTGATCCGGAGACCCA 
GABPA   




ALB (-) 194 
 
above 
TERT 163 F CACCCGTCCTGCCCCTTCA 
R CTGCCTGAAACTCGCGCC 
GSC   
























H3K27me3   
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MYT1 (+) 135 
 
above 
Actin (-) 83 
 
above 
TERT 163 above 
Citation denotes primers from previously published articles. (+) denotes the positive control gene 































Sequences (5’-> 3’) 





























Table S6: sgRNAs for CRISPR/Cas9 Editing  
Cutting Positiona sqRNA Sequence (5’-> 3’) 
-147/-148 GCGCCCCGTCCCGACCCCTCC 
Upstream boundary of 
eGFP 
GATTCCACAGGGTCGACCACC 
Downstream Boundary of 
eGFP 
GTCTTCGGACCTCGCGGCCC 





















Table S7: Primers for CRISPR/Cas9 Editing Confirmation  
Primer Name Sequences (5’-> 3’) 
Step 1 L arm  (121) F CGTCCAGGGAGCAATGCGT 
R ACTTTCCACACCTGGTTGCTGAC 




Step 2 Exon 1 SNP F CGCGGCGCGAGTTTCAGGCA 
R GTGGCCAGCGGCAGCACCTC 
Step 2 Final TERT F CACCCGTCCTGCCCCTTCA 
R CTGCCTGAAACTCGCGCC 
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B. Avin, Y. Wang, I. Lee, R. Workman, L. Florea, W. Timp, C.B. Umbricht, and M.A. Zeiger. 
Understanding the Epigenetic Regulation of Alternative Splicing of Human Telomerase Reverse 
Transcriptase. Poster presented October 2017 at the Annual Meeting of the American Thyroid Association. 
B. Avin, Y. Wang, I. Lee, R. Workman, L. Florea, W. Timp, C.B. Umbricht, and M.A. Zeiger. 
Understanding the Epigenetic Regulation of Alternative Splicing of Human Telomerase Reverse 
Transcriptase. Poster presented May 2017 at the Johns Hopkins Department of Surgery’s Research Day.  
B. Avin, Y. Wang, I. Lee, R. Workman, L. Florea, W. Timp, C.B. Umbricht, and M.A. Zeiger. The Link 
between Human Telomerase Reverse Transcriptase (hTERT) Promoter Methylation Status and Alternative 
Splicing in Thyroid Cancer. Poster presented September 2016 at the Annual Meeting of American Thyroid 
Association. Chosen as a Featured Poster for the Trainee Poster Contest. 
B. Avin, K. Jameson, P. Frick, D. Tyson, L. Estrada, and V. Quaranta. Identification of Biomarkers 
Correlating with Drug Response in Non-Small Cell Lung Cancer. Poster presented April 2015 at the 
Annual Meeting of the American Association for Cancer Research, Undergraduate Student Caucus. 3rd 
Place Award for National Undergraduate AACR Poster Competition. 
B. Avin, K. Jameson, P. Frick, D. Tyson, L. Estrada, and V. Quaranta. Identification of Biomarkers 
Correlating with Drug Response in Non-Small Cell Lung Cancer. Poster presented August 2014 at NCI’s 
ICBP Summer Cancer Research Virtual Poster Session. 
B. Arnson, B. Avin, J. Tumolo, M. Reinhart, C. Ingram-Smith, K. Smith. Characterization of the 
Cryptococcus neoformans Acetyl-CoA Synthetase. Poster presented October 2013 at the Cell Biology of 
Eukaryotic Pathogens Symposium, Clemson University. 
B. Avin, S. Brutus, K. Mills Lujan and A.H. Corbett. Molecular Modeling of Neurodegenerative Disease 
Pontocerebellar Hypoplasia Type 1: Functional Studies of S. cerevisiae Rrp40. Poster presented August 
2013 at the Emory University SURE Poster Session. Awarded Most Popular Poster Award for Summer 
Undergraduate Research Experience Program. 
REVIEW ARTICLES 
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ThyCa National Representative at AACR Scientist to Survivor Program          2016 
SCIENCE POLICY OUTREACH 
Johns Hopkins Science Policy Group President                 2019-2020 
Selected American Association for Cancer Research (AACR) Early-Career Hill Day Participant       2019 
AACR Panelist- How to Effectively Advocate for Cancer Research and Science-Based Policy       2019 
Johns Hopkins Science Policy Group Advocacy Chair               2017-2019 
Selected Representative for the AAAS Catalyzing Advocacy in Science Engineering Program              2019 
 
PROFESSIONAL ASSOCIATIONS 
American Association for the Advancement of Science 
American Society of Human Genetics 
American Association for Cancer Research  
American Thyroid Association 
